Digital Pathology Podcast

Send us Fan MailDo you really need a scanner, whole slide images, and AI infrastructure before you can start in digital pathology?In this episode, I argue that you do not.I'm Dr. Aleksandra Zuraw, veterinary pathologist and digital pathology educator, and this talk is about a belief I hear all the time: I don't have the tools yet, so there is no point learning digital pathology. I used to think that too. When I was training in Berlin, there was one Leica 6-slide scanner, and it felt like digital pathology was only for a small group of chosen people. That experience made the field feel distant, exclusive, and not really available to beginners. What changed for me was not a new scanner. It was a small project.I needed a more consistent way to quantify a senescence marker in archived skin samples, so I used a microscope camera, captured images, opened them in Microsoft Paint, and manually marked cells with colored dots. It was scrappy. Very low tech. But it was also digital, consistent, and verifiable. That project became my first real step into digital pathology and helped me get my first job in the field, where I worked between pathologists and image analysis scientists on biomarker quantification and patient stratification problems. That is the core point of this episode: knowledge unlocks technology.Scanners matter. AI tools matter. But the deeper bottleneck is whether enough people understand how to use these tools, ask good questions, and connect pathology expertise with digital workflows. That is why this episode is really about readiness. Not readiness of the hardware. Readiness of the people.I also talk about Dr. Taladzer from Pakistan, whose story makes this point even more clearly. At the time, Pakistan had around 220 million people, about 500 pathologists, and zero scanners. She still started learning digital pathology during COVID using a microscope and camera, joined the Digital Pathology Association, taught herself from papers and online resources, and kept going even after multiple AI vendors rejected her because she did not have whole slide images. Eventually, she found a DIY image analysis platform, learned to annotate and train models on static images, completed projects quickly, and went on to publish more than 10 digital pathology papers without ever using WSI.Why should you listen?Because this episode is for pathologists and lab leaders who are interested in digital pathology but still feel stuck at the beginning. It is for people waiting for permission, perfect infrastructure, or a formal roadmap. And it is for trailblazers who came back from a meeting or conference energized, but need a practical way to turn that energy into action before it fades.I also address an important AI question near the end: How do we know an AI model is good enough for pathology? I talk about why models are only as good as the pathologist annotations used to train them, why concordance between pathologists matters, how orthogonal labels like IHC can improve model quality, and why pathologists still need to stay in the loop as these systems develop and get deployed.If you are trying to figure out where to start, this episode gives you a practical answer: start where you are. Start with what you have. Start learning now.Episode Highlights00:00 – Why the real barrier to digital pathology is usually not the hardware 00:33 – What it feels like to be at the beginning of the digital pathology journey 02:50 – My first practical digital pathology project using a microscope camera and Microsoft Paint 05:37 – How that low-tech project led to my first digital pathology job 08:52 – Why knowledge, not infrastructure, is the real unlock 09:57 – Dr. Taladzer's story: starting digital pathology in Pakistan with zero scanners 12:03 – What happened after repeated vendor rejection and why persistence mattered 14:39 – The “forgetting loop” vs the “commitment loop” after conferences 16:48 – Practical next steps: book, PubMed alerts, journal clubs, webinars, vendor resources 18:52 – Why I believe digital pathology is the gateway to faster diagnosis 20:00 – How to think about whether an AI model is really ready for pathologyResources MentionedDigital Pathology 101 – free book recommended as a starting point for learning digital pathology. Digital Pathology Association – mentioned as a learning resource and professional community. PubMed alerts for AI and digital pathology. Journal clubs – mentioned as one way to keep learning consistently. Webinars and vendor resources – suggested as practical ways to keep building knowledge. A4A – the DIY image analysis platform that supported Dr. Taladzer's early work with static image annotation and model training. Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailWhy are pathology vendors still speaking different image languages when radiology solved that problem decades ago?In this episode of DigiPath Digest #46, I talk through four papers that all point to a bigger issue in digital pathology: we are not only dealing with better algorithms. We are dealing with interoperability, workflow design, explainability, and whether the field is actually ready to use these tools well.I start with DICOM in digital pathology, because I think this is still one of the most important infrastructure questions in the field. Digital pathology has clear value for consultation, image analysis, archival, and workflow, but vendor-specific whole slide image formats still create silos. In the episode, I explain why DICOM matters, why adoption is still low, how the multi-resolution pyramid works, and why this is really about enterprise imaging and future-proofing, not just file conversion. Then I move into kidney transplant rejection, where the paper makes a strong case for multimodal precision diagnostics. Creatinine is late. Antibody testing can miss important biology. Biopsies can miss the area that matters. So the opportunity is not to replace pathology, but to combine biomarkers, biopsy, and machine learning in a way that is more useful than any one signal alone. I also talk about explainability here, because if a model gives a risk score, we need to know what contributed to it. The third paper focuses on perineural invasion in solid tumors, and I liked this one a lot because it shows how AI can help standardize something that is clinically important but still inconsistently detected and reported. Perineural invasion is not just a passive pathway of spread. The biology is more active than that, and the quantification can go far beyond a simple yes-or-no answer. This is a good example of where digital pathology can do something humans cannot realistically do by eye at scale. The last paper is on gastric cancer immunohistochemistry biomarkers and advanced quantification, including HER2, PD-L1, mismatch repair, and CLDN18.2. This section is really about complexity. We are now asking pathologists to visually score biology that is getting harder and harder to summarize consistently, especially when markers, spatial context, and multiplexing all start to matter at once. I make the case that computational pathology is becoming necessary here, not because pathologists are failing, but because the biology is outgrowing purely visual workflows. What ties these four papers together is simple: digital pathology is not only about remote reading anymore. It is about interoperability, quantification, explainable AI, and making pathology more precise in places where the old workflow is reaching its limit. If you are a pathologist, lab leader, or digital pathology trailblazer trying to figure out what actually matters right now, this episode will help you connect the dots.Episode Highlights 07:41 – Why DICOM still matters if we want digital pathology systems to work together. 14:39 – Current adoption of SVS, MRXS, and DICOM, and why DICOM is still lagging. 16:44 – How the DICOM whole slide image pyramid works and why it matters for workflow. 24:29 – Why kidney transplant rejection is still difficult to diagnose with any single marker. 29:18 – Why perineural invasion is clinically important and still inconsistently reported. 34:44 – How AI can quantify tumor-nerve relationships more consistently than visual review alone. 46:39 – Why gastric cancer biomarker scoring is getting too complex for purely visual workflows. 54:55 – Multiplexing, spatial biology, and why explainable AI matters in biomarker interpretation. 01:04:01 – What is really blocking digital pathology adoption: cost, workflow, regulation, or mindset? Resources mentionedDICOM / digital pathology interoperability paper https://pubmed.ncbi.nlm.nih.gov/42093730/Kidney transplant rejection, biomarkers, and artificial intelligence https://pubmed.ncbi.nlm.nih.gov/42073482/Perineural invasion in solid tumors with AI and machine learning applications https://pubmed.ncbi.nlm.nih.gov/42100436/Gastric cancer IHC biomarkers, advanced detection methods, and perspectives https://pubmed.ncbi.nlm.nih.gov/42075555/Digital Pathology Place https://digitalpathologyplace.comDigital Pathology 101 Free PDF book mentioned at the end of the episode through Digital Pathology Place.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailWhat if the most frightening part of a pathology report is not the word cancer, but the silence that follows?In this episode of the Digital Pathology Podcast, Dr. Aleksandra Zuraw talks with Michele Mitchell—breast cancer survivor, caregiver, national patient advocate, and longtime volunteer across Michigan Medicine, ASCP, the Digital Pathology Association, and MyPathologyReport.ca—about what happened when she saw her own cancer slide years after treatment. That moment changed how she understood her disease, her risk, and her role as a patient advocate.This is not just a patient story. It is a digital pathology implementation story.The episode looks at how digital pathology removes practical barriers to sharing slides, why pathology clinics matter, and what becomes possible when pathologists move from being hidden in the background to becoming direct contributors to patient understanding. Michelle and Dr. Aleks talk through the communication gap around pathology reports, the emotional cost of delayed explanation, and the real-world workflow of pathology clinic visits built to help patients review their slides with the pathologist who made the diagnosis.They also discuss what the 21st Century Cures Act changed for patients, why immediate access to reports without interpretation can still create fear, and how pathology clinics can bridge the gap between raw data and real understanding. The conversation gets practical too: how patients can request a pathology clinic visit, what virtual pathology consults can look like, how billing and workflow concerns are already being addressed, and why the infrastructure question is smaller than many people assume.If you work in digital pathology, pathology informatics, patient communication, or implementation, this episode is a reminder that visibility is not extra. It is part of the value proposition. And for pathologists who worry this is too far outside the traditional role, the episode offers a grounded counterpoint: the workflows, templates, billing structures, and virtual options already exist.Highlights00:00 – Why pathology needs to become more patient-centered Michele frames the core problem clearly: what often scares patients is not only cancer, but the silence around the diagnosis. 00:34 – How digital pathology changes the patient experience Digital slides make it possible for patients to see their diagnosis, compare normal and abnormal tissue, and ask better questions. 11:13 – What happened when Michele saw her cancer for the first time More than a decade after treatment, seeing her own slide changed how she understood her grade, her risk, and her daily health decisions. 16:19 – Why visual pathology can change adherence and lifestyle Michele explains how the image-based explanation became a practical turning point, not just an emotional one. 20:43 – The case for direct pathologist-patient communication The episode reviews why this can improve clarity, treatment understanding, clinic efficiency, and even professional satisfaction for pathologists. 38:40 – What a pathology clinic actually looks like From preparation and consent to slide review, plain language, empathy, and follow-up, the workflow is much more concrete than many people assume. 45:35 – ASCP's certification workshop for pathology clinics Michele describes the national effort to make pathology clinics reproducible, scalable, and easier to implement. 49:32 – What the 21st Century Cures Act changed Patients now get near real-time access to reports, but that access still needs interpretation, context, and support. 01:03:23 – Pushback, logistics, and why the barriers are not where people think Time, reimbursement, scheduling, and virtual setup are addressed directly with examples already in practice. 01:16:57 – The future: patient-friendly reports, AI, and pathology as part of the care team The episode closes on a practical vision: not hype, but tools and workflows that already exist and can be connected now. Resources mentionedDigital Pathology Place – website and educational platform referenced by Dr. Aleks as the home for her work and resources. Digital Pathology 101 – Dr. Aleks's book, referenced in the broader discussion of patient and pathologist education. Michigan Medicine breast pathology clinic – launched in 2023 as a patient-facing breast pathology clinic model. ASCP pathology clinic certification workshop – national workshop co-developed to help institutions build pathology clinics. 21st Century Cures Act – legal framework behind near real-time patient access to pathology reports and related health data. MyPathologyReport.ca – patient-friendly pathology education resource reviewed with patient advocate involvement. American Cancer Society Reach to Recovery – support resource mentioned for breast cancer patients. Scanslated – patient-friendly report interface discussed as part of a future-facing model for pathology communication. Virtual pathology consults/telehealth setup – discussed as a scalable way to lower implementation friction.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailDigiPath Digest #45 asks a practical question: can AI in pathology move from correlation to real clinical use? In this episode, I review four papers that push on that question from different angles: computational pathology moving toward morphology-driven molecular inference, the current state of digital cytopathology and AI, multi-omics and precision oncology in hepatocellular carcinoma, and AI literacy in veterinary education. What ties them together is not model performance alone. It is the harder question of validation, workflow fit, quantitative use, ethics, and human oversight.In the first paper, I talk about computational pathology as more than pattern recognition. The focus is on morphology-driven molecular inference, digital biomarkers, and why spatial omics matters as biological ground truth. I also discuss why continuous quantitative scoring is more useful than forcing biology into rough scoring buckets. The second paper focuses on digital cytopathology. Cytology was early for FDA-cleared AI in cervical screening, but non-gynecologic cytology is still much harder to digitize because of specimen variability and workflow complexity. I also cover telecytology, rapid onsite evaluation, automation, and quality control. The third paper looks at hepatocellular carcinoma and AI-driven precision oncology. This part is about using AI and machine learning to integrate genomics, transcriptomics, proteomics, metabolomics, radiomics, and pathology to support biomarker discovery, tumor microenvironment analysis, and treatment stratification. The fourth paper may be the most broadly useful. It proposes an AI literacy curriculum for veterinary education that covers AI fundamentals, machine learning evaluation, LLMs, ethics, liability, and academic integrity. I think that matters far beyond veterinary medicine, because if clinicians are expected to use AI tools responsibly, AI literacy cannot stay optional. Highlights 00:01 Welcome and overview of the four papers 03:02 Computational pathology and morphology-driven molecular inference 11:01 Digital cytopathology, telecytology, and QC 20:47 AI/ML in hepatocellular carcinoma precision oncology 31:04 AI literacy in veterinary education 47:42 Final takeaways and Digital Pathology 101 update ResourcesComputational Pathology as a Mechanistic Discipline: From Morphology to Molecular Data https://pubmed.ncbi.nlm.nih.gov/42052846/Advances in Digital Cytopathology and Artificial Intelligence Applications https://pubmed.ncbi.nlm.nih.gov/42046894/Navigating the Labyrinth of Hepatocellular Carcinoma: Leveraging AI/ML for Precision Oncology https://pubmed.ncbi.nlm.nih.gov/42065059/Curriculum Framework for Artificial Intelligence Literacy in Veterinary Education Front Vet Sci. 2026;13:1801756 Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailWhere is AI in pathology actually becoming useful right now? In this episode of DigiPath Digest, I review 4 new PubMed papers across digital pathology, whole slide imaging (WSI), computational pathology, medical education, forensic pathology, and breast cancer AI. We look at a deep learning tool for coronary artery stenosis measurement in forensic autopsies, an AI-powered digital pathology model for renal pathology education, an open-source quality control tool for prostate biopsy whole slide images, and a breast cancer stage prediction model built for resource-constrained settings using low-magnification H&E slides. I also share updates on the upcoming second edition of Digital Pathology 101 and the decision to make AI paper summaries public on the podcast feed to help busy pathology professionals stay current. Highlights  [01:28] Update on the upcoming second edition of Digital Pathology 101 and the release of public AI paper summaries for faster literature review. [05:22] Paper 1: Deep learning for coronary artery stenosis evaluation in forensic autopsies using whole slide imaging. Why objective stenosis measurement matters, how the model outperformed visual estimates, and why this could affect adoption in forensic pathology. [15:18] Paper 2: AI-powered digital pathology with case-based teaching in renal education. A practical discussion on annotated digital slides, flipped classroom learning, and how digital pathology can improve pathology education and diagnostic reasoning. [21:34] Paper 3: Open-source AI for quantitative quality control in prostate biopsy whole slide images. Why WSI quality control matters, what PathProfiler measures, and how automated QC can support remote pathology workflows. [32:38] Paper 4: Breast cancer stage prediction from H&E whole slide images in resource-constrained settings. A look at low-magnification AI, vision transformers, and what moderate performance can still mean when access to advanced testing is limited. [45:06] Closing thoughts, invitation to vote for future AI paper summaries, and a final reminder to download Digital Pathology 101. Resources Paper 1: Development of a deep learning-based tool for coronary artery stenosis evaluation in forensic autopsies using whole slide imaging PubMed: https://pubmed.ncbi.nlm.nih.gov/41998396/Paper 2: Integrating AI-Powered Digital Pathology With Case-Based Teaching: A Novel Paradigm for Renal Education in Medical School PubMed: https://pubmed.ncbi.nlm.nih.gov/41995002/Paper 3: Application of an open-source AI tool for quantitative quality control in whole slide images of prostate needle core biopsies - a retrospective study PubMed: https://pubmed.ncbi.nlm.nih.gov/41994924/Paper 4: Deep-learning-based breast cancer stage prediction from H&E-stained whole-slide images in resource-constrained settings PubMed: https://pubmed.ncbi.nlm.nih.gov/41993946/Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Deep-learning-based breast cancer stage prediction from H&E-stained whole-slide images in resource-constrained settings. Bedőházi Z, Biricz A, Kilim O, et al. Journal of Pathology Informatics 21 (2026) 100644.Episode Summary:Welcome back, Trailblazers! In this Journal Club deep dive of the Digital Pathology Podcast, we flip the core assumption of microscopic precision on its head. Can an AI accurately predict pathological breast cancer stages (pTNM I-III) from a blurry, high-altitude 2.5x magnification snapshot? We explore a 2026 study that strips away standard high-resolution data to build a highly efficient, resource-aware AI diagnostic tool for clinics lacking supercomputers. We unpack the math, the models, and a haunting revelation about what primary tumors can tell us about distant metastasis.In This Episode, We Cover:• The Compute Bottleneck: Why the digital pathology AI revolution is leaving resource-constrained clinics behind, and how dropping from the standard 40x to 2.5x magnification slashes image patch extraction by 256 times, bypassing massive hardware and server requirements.• The "Airplane View": How the AI compensates for the loss of microscopic cellular details (like mitosis or cellular atypia) by relying on macroscopic features, identifying disease through overall tumor growth patterns and broad architectural disruption.• Vision Transformers & "Puzzle Bags": Why the UNI foundation model—a vision transformer fine-tuned on the BRACS dataset—outperforms older convolutional networks (like ResNet-50) by mapping long-range spatial dependencies across the entire image patch simultaneously. Plus, how Multiple Instance Learning (MIL) acts as a targeted "puzzle bag," mathematically weighting critical cancer data and ignoring irrelevant background noise.• The Real-World Stress Test: The model's solid performance on the internal Semmelweis dataset versus the massive external Nightingale cohort, where unsupervised data cleaning with t-SNE and DBSCAN clustering automatically deleted garbage data. We also discuss the AI's struggle with the TCGA-BRCA dataset due to severe domain shift from heterogeneous tissue preparation, specifically the structural tissue damage caused by frozen sections.• The "Messy Middle" and Clinical Triage: The model's tendency to struggle with Stage II breast cancer and the critical clinical danger of under-staging advanced Stage III cancers. We discuss why this WSI-only baseline isn't replacing human pathologists, but rather serves as an automated "sorting hat" for incomplete medical records or a highly tunable "smoke detector" to route suspicious slides for immediate manual review.Key Takeaway:The AI successfully predicted overall cancer stage—which inherently includes distant lymph node metastasis—by looking only at the primary tumor's architectural disruption, without ever evaluating a single lymph node slide. This proves that vital systemic biological secrets are hiding in plain sight in the macroscopic view of standard H&E slides, offering a phenomenal proof-of-concept for global health equity in resource-constrained settingsSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Integrating AI-Powered Digital Pathology With Case-Based Teaching: A Novel Paradigm for Renal Education in Medical School. Zhou H, Cui L. Clin Teach 2026; 23(3):e70421. doi: 10.1111/tct.70421.Episode Summary: In this journal club episode tailored for healthcare trailblazers, we explore a massive paradigm shift in medical education. We examine a 2026 perspective article that uses the notoriously complex field of renal pathology as a stress test for a brand-new teaching model. Moving away from dark lecture halls and static, perfect images, we discuss what happens when artificial intelligence is actively combined with flipped classrooms, fundamentally redefining what it means to be a competent physician in the digital age.In This Episode, We Cover:• The "Bottleneck" of Renal Pathology: Why the kidney is the ultimate teaching hurdle. Students must translate the dense, flattened 2D reality of an H&E stain into an understanding of a patient's complex systemic autoimmune response.• The Danger of the "Curated Reality": Why traditional teaching methods that rely on textbook-perfect, heavily curated slides create "brittle" mental models. When students finally encounter messy, real-world biopsies with overlapping, ambiguous pathologies, the traditional educational foundation falls apart.• The "Spell Checker" for Histopathology: How collaborative AI elevates Whole Slide Imaging (WSI) beyond just high-resolution screens. The AI acts as a concurrent guide, using pixel-level pattern recognition to highlight regions of interest simultaneously and simulate the complex reasoning process of an expert pathologist.• The Case-Based Flipped Classroom (CBFC): The pedagogical engine that anchors these AI tools in clinical reality. Instead of passive lectures, students are handed the "detective's case file" beforehand to actively interrogate annotated slides, synthesizing diverse data streams to defend diagnoses in collaborative groups.• Redefining Medical Competence (The "Clinical Editor"): Why the new bottleneck in medical education isn't memorization—it's critical appraisal. We discuss the necessity of teaching "digital literacy," training students to skeptically manage AI, recognize its blind spots (like confusing a physical tissue fold for an abnormality), and actively audit the algorithm against the messy human reality of the patient.• The Impending Culture Collision: A look at the fascinating future where freshly minted, AI-native residents enter a legacy clinical workforce still transitioning away from physical glass slides, potentially reversing traditional medical hierarchies in the hospital.Key Takeaway: The goal of modern medical education is no longer just memorizing histological patterns, as that heavy lifting is being outsourced to algorithms. By fusing AI-powered digital pathology with the necessary friction of case-based learning, we are training a new generation of diagnosticians to view AI not as a crutch, but as a powerful collaborative tool that must be thoughtfully scrutinized and audited for safe patient careSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: Advancements in bone marrow biopsy: the role of omics and artificial intelligence in hematologic diagnostics. Maryam Alwahaibi and Nasar Alwahaibi. Front. Med. 2026; 13:1772478.Episode Summary: In this journal club deep dive, we explore a paradigm shift in hematopathology, moving from 19th-century visual assessments to the cutting edge of precision medicine. We examine a 2026 review that unpacks how combining artificial intelligence with multi-omics technologies is transforming the traditional bone marrow biopsy from a static, subjective snapshot into a live, interactive, predictive 3D map. We ask: What happens when deep learning can predict underlying genetic mutations just by analyzing the visual shape and texture of a cell?.In This Episode, We Cover:The Breaking Point of Traditional Diagnostics: Why the 150-year-old gold standard of H&E staining and human visual assessment is hitting a biological and operational wall, plagued by subjectivity, high variability, and observer fatigue.The Multi-Omics Multiverse: Moving beyond standard genomics to unpack the complex biological machinery of the marrow, including:Epigenomics: The biological "switches," like DNA methylation, that control cell fate and can kick off malignant transformation without altering the underlying DNA sequence.Lipidomics: How cellular fats form specialized signaling rafts that actively remodel the marrow's communication network.Microbiomics (The Gut-Marrow Axis): How systemic inflammation driven by gut dysbiosis acts like a massive "traffic jam" that indirectly disrupts local bone marrow homeostasis and blood cell production.AI as the Ultimate Analytical Partner: How artificial intelligence serves as a bridge between physical tissue morphology and high-dimensional molecular data. We discuss AI tools like MarrowQuant for objective cellularity mapping and the Continuous Index of Fibrosis (CIF) that replaces clunky human guesswork with a granular, predictive metric.Predicting Genotype from Phenotype: The revolutionary capability of deep learning models to predict underlying genetic mutations (like TET2 or del 5q MDS) purely from the subvisual, spatial arrangement and shape of cells on a standard slide.Roadblocks and Solutions: Why this technology isn't universally adopted yet. We break down the "black box" problem of AI, the brittleness of algorithms in different clinical settings, and how innovations like Federated Learning and Explainable AI (using heat maps) are overcoming these hurdles.Key Takeaway: The integration of AI and multi-omics is redefining our understanding of bone marrow diseases. By uncovering invisible molecular machinery and objectively translating it through transparent algorithms, we are moving away from subjective human bottlenecks toward a highly personalized, predictive model of hematologic care.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: Artificial intelligence in clinical oncology: Multimodal integration and translational development. Ruichong Lin, Zhenhui Zhao, Zhonghai Liu, Jin Kang, Kang Zhang, Xiaoying Huang, Yunfang Yu. Cancer Letters 2026; Volume 649, 218493.Episode Summary: In this journal club deep dive, we explore how cutting-edge AI is fundamentally rewriting the rules of cancer diagnostics. We examine a comprehensive 2026 review on clinical oncology that highlights the shift from narrow, single-modality algorithms to highly sophisticated multimodal AI. We discuss how machines are learning to cross-reference patient charts, genomic data, and medical imaging simultaneously to achieve unprecedented feats—like accurately predicting tumor mutations without ever performing a physical biopsy. Plus, we explore the controversial but necessary world of "computational hallucinations" or synthetic data, which is currently being used to solve diagnostic blind spots.In This Episode, We Cover:• The Fragmentation Bottleneck: Why keeping radiology, pathology, genomics, and clinical history in isolated silos limits our ability to treat the whole patient, and why single-modality AI suffers from severe diagnostic "tunnel vision".• Cross-Modal Attention & Non-Invasive Biopsies: How models like LUCID essentially mimic the deductive reasoning of a multidisciplinary tumor board. By utilizing cross-modal attention mechanisms, LUCID dynamically shifts focus between CT scans, routine labs, and text-based clinical charts to predict EGFR gene mutations in lung cancer entirely non-invasively.• Graph Neural Networks (GNNs) & Tumor Social Networks: A look at the NePSTA framework, which uses GNNs and spatial transcriptomics to treat the tumor microenvironment like a mathematical topology. By mapping the "social network" of cells, it can rapidly molecularly subtype notoriously ambiguous central nervous system (CNS) tumors in minutes.• Computational Hallucinations: Introducing MINIM, a generative AI foundation model that creates statistically valid, photorealistic synthetic medical images (like optical CT or chest X-rays) for rare diseases based on textual descriptions. We discuss how intentionally generating these synthesized images solves the critical "data scarcity" problem and directly improves real-world diagnostic accuracy.• The Reality Check - Distribution Shifts: The dangerous logistical reason why an AI model boasting near-perfect accuracy at a massive urban academic center might fail completely in a rural clinic due to differing scanner calibrations and population demographics. We emphasize why the field must transition away from retrospective "vanity metrics" and toward clinically trustworthy prospective validation.• The Virtual Cell Paradigm: A staggering look into the near future where AI constructs completely accurate, computationally interactive digital twins of a patient's cancer. This framework allows doctors to test different drug regimens and simulate cellular responses mathematically in silico before ever administering medicine to the actual patient.Key Takeaway: Multimodal AI proves that cancer diagnostics must go beyond isolated data points. By dynamically synthesizing highly fragmented clinical information and utilizing synthetic imaging to overcome rare disease data scarcity, AI is pushing oncology into an era of robust, individualized molecular phenotyping. Ultimately, these innovations are replacing risky, invasive testing with precSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Spatial omics and AI for clinically actionable cancer biomarkers. Reitsam NG. PLoS Med 2026; 23(4): e1005049.Episode Summary: In this deep dive, we explore how artificial intelligence and spatial omics are fundamentally rewriting the rules of cancer diagnostics. We break down a 2026 editorial that challenges a deceptively simple question driving modern oncology: Is a tumor "positive" or "negative" for a biomarker? As targeted cancer therapies evolve, this binary thinking is failing us. We discuss why mapping where and how much of a therapeutic target exists is crucial, and how AI is stepping in to solve the reproducibility issues human pathologists face when making borderline diagnostic calls.In This Episode, We Cover:• The Illusion of "Positive" vs. "Negative": Why the basic premise of modern cancer therapies—like antibody-drug conjugates (ADCs)—often falls apart in reality when we ignore the spatial heterogeneity of a tumor.• The Power of Computational Pathology: How AI is transforming subjective, qualitative estimates into continuous, reproducible data, scaling the quantification of complex biomarkers like PD-L1 and TROP2.• "Virtual" Proteomics: The fascinating concept of using AI models to infer high-dimensional spatial information and immune maps directly from standard, routine H&E stained slides.• The HER2 Bottleneck: A real-world look at the breast cancer drug T-DXd, which now demands pathologists distinguish between "HER2-low" and "HER2-ultralow". While human agreement drops below 70% at these fuzzy decision boundaries, AI steps up with a staggering ~97% sensitivity.• Three Shifts for the Future: Why clinical trials and routines must adopt continuous measures (like percentage of expressing cells), demand longitudinal repeat testing at disease progression, and utilize adaptive trial platforms.• Bridging the Gap to Reality: The massive hurdles preventing widespread adoption—such as equipment costs exceeding $250,000 and massive data storage needs. We discuss why a hybrid workflow that bolsters routine pathology with deployable AI is the best path forward to prevent widening global health disparities.Key Takeaway: The future of precision oncology isn't just about finding new drug targets; it's about fundamentally changing how we measure them. By moving away from rigid binary thresholds and using AI to map the continuous, spatial reality of tumors, we can unlock the true potential of targeted therapies. However, achieving this diagnostic ecosystem requires overcoming significant financial and systemic hurdles—such as updating reimbursement pathways and proficiency testing—to ensure these life-saving insights are accessible across all healthcare settings.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailI did something I've never done before for this episode — I went live from the middle of a national park. This is DigiPath Digest #42, broadcasting from the Great Sand Dunes National Park in Colorado via Starlink from my family road trip. Yes, it actually worked. And so did the papers.This episode covers four papers that all ask the same uncomfortable question from different angles: how close is AI to being genuinely useful in real pathology practice — and what's still standing in the way? From LLMs interpreting cervical Pap smears, to AI guiding breast cancer treatment decisions from a simple H&E slide, to a practical roadmap for bringing generative AI into oncology workflows — this one covers a lot of ground.I also introduced something new: my AI-powered paper summary podcast subscription. For $7 a month, AI hosts summarize digital pathology literature in a journal-club style so you can stay current without spending hours reading abstracts. I walk through how it works and why I built it.What we cover:[00:00] Going live from the wilderness — Starlink, sand dunes, and a very cold morning[02:01] How I use AI-generated audio summaries to prep for each DigiPath Digest[03:19] Paper 1: Can LLMs like ChatGPT and Gemini interpret cervical cytology? Spoiler: ~47–48% exact concordance — promising, but not there yet[10:23] Bonus: My new AI-powered paper summary subscription — $7/month, journal-club style[14:05] Paper 2: AI in oral oncology — CNNs for early lesion detection, multimodal prognostics, and the real barriers still blocking clinical adoption[20:28] Paper 3: Generative AI in oncology — from chat tools to agentic EHR-integrated assistants, and why augmentation is the goal, not automation[25:35] Paper 4: Computational pathology in breast cancer — predicting BRCA1/2, HER2, Oncotype DX, and treatment response from standard H&E slides[31:39] Final thought: the floor just got raised for all of us — how I think about new technology in pathologyResources & Links:Paper 1 – LLMs & Cervical Cytology (PubMed): https://pubmed.ncbi.nlm.nih.gov/41931983/Paper 2 – AI in Oral Oncology (PubMed): https://pubmed.ncbi.nlm.nih.gov/41930554/Paper 3 – Generative AI in Oncology Practice (PubMed): https://pubmed.ncbi.nlm.nih.gov/41930309/Paper 4 – AI & Digital Pathology in Breast Cancer (PubMed): https://pubmed.ncbi.nlm.nih.gov/41930306/Watch on YouTube: https://www.youtube.com/live/O2hOU4gM0Bk?si=oH8iJ8HiBb29USG3Digital Pathology Place: https://www.digitalpathologyplace.comSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:How to bring generative AI to oncology practice. D. Truhn & J. N. Kather. ESMO Real World Data and Digital Oncology 2026.Episode Summary:In this journal club deep dive, we step out of the theoretical sci-fi hype of artificial intelligence and look at a practical, real-world roadmap for bringing Generative AI into oncology. We examine a 2026 paper that maps out the trajectory for deploying Large Language Models (LLMs) to combat the overwhelming cognitive load of modern cancer care. Rather than replacing clinicians, this episode explores how AI can synthesize massive amounts of unstructured data—like dense pathology narratives and shifting molecular reports—so doctors can get back to practicing medicine instead of acting as data entry clerks.In This Episode, We Cover:• The Data Avalanche in Oncology: Why the shifting landscape of decades of patient histories, clinical trial registries, and handwritten notes creates an information load that human cognition simply wasn't evolved to process all at once.• How LLMs Actually "Think": Why predicting the "next word" based on massive training data allows AI to mimic medical reasoning and organize complex clinical concepts—like linking a BRAF mutation directly to a specific inhibitor without looking up a rulebook.• The Three Evolutionary Steps of AI Complexity: ◦ Step 1: Stand-alone Models: The "closed-book exam." These models (like early ChatGPT) are frozen in time with their original training data and have zero access to new clinical trials or FDA updates. ◦ Step 2: Retrieval-Augmented Generation (RAG): The "open-book exam." The AI searches continually updated external databases and guidelines before answering, significantly reducing fabricated answers, or "hallucinations". ◦ Step 3: Agentic AI: The ultimate goal. Fully functioning "research assistants" that can iteratively reason, plan steps, and invoke external software tools (like lab APIs and medical calculators) to complete complex tasks like proposing tumor board summaries.• The Deployment Roadblocks: Why you can't just drop an autonomous agent into a fragmented hospital IT network built in 2005. We unpack strict security silos, audit logs, and the dangerous reality of "domain shift"—where an AI trained perfectly at Johns Hopkins might silently fail at a community clinic simply due to different doctor shorthand or microscopic slide scanner colors.• The Human Element & Automation Bias: The hidden dangers of junior doctors losing their clinical intuition (deskilling) and why system design must force the AI to "show its work" with intentional friction to prevent doctors from blindly clicking accept on a hallucinated treatment plan.• Your Edits Are the Future: A fascinating look at how a clinician's daily administrative annoyances—every strike-through and manual correction of an AI draft—serve as the ultimate, high-value ground-truth data to train the next generation of oncology AI.Key Takeaway:The destination we are driving toward is augmentation, not automation. By handling massive information synthesis, uncovering patterns, and explicitly showing its work, AI can act as a tireless assistant that improves routine care, while leaving the final, nuanced clinical judgment exactly where it belongs: with the human physician.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: Can large language models like ChatGPT and Gemini interpret cervical cytology accurately? Saroja Devi Geetha. Annals of Diagnostic Pathology 2026; Volume 83, 152641.Episode Summary: In this journal club deep dive, we explore what happens when advanced artificial intelligence is thrown into the visually chaotic realm of human biology. We examine a 2026 study evaluating whether two massive multimodal models—GPT-5 and Gemini 2.5 Pro—can accurately read digital cervical Pap smears without any prior fine-tuning,,. We unpack how these general-purpose models perform on highly specialized visual tasks, revealing that while they aren't ready to fly solo, they exhibit fascinating and distinct diagnostic "personalities" that will undoubtedly reshape the future of the pathology lab,.In This Episode, We Cover:• The "Textbook" Test Setup: How researchers tested the baseline visual reasoning of GPT-5 and Gemini 2.5 Pro by feeding them 100 curated, gold-standard digital Pap test images from the Hologic Education Site to classify using the Bethesda System,,.• The Clinical Reality Check: While the models only achieved a coin-toss exact diagnostic match rate (47% for GPT-5 and 48% for Gemini), their accuracy jumped to 66% when evaluating clinical management protocols—proving they are beginning to grasp the underlying severity and medical consequences of cellular abnormalities,,.• The Over-Anxious Resident (Gemini 2.5 Pro): Gemini acted like a highly sensitive but unrefined trainee, hitting 84% sensitivity and expertly spotting infectious organisms (71%),,. However, its tendency to confuse dense, overlapping cellular clumps with high-grade squamous intraepithelial lesions (HSIL) led to massive overcalling, dragging its specificity down to 71% and creating a risk of false alarms,.• The Big-Picture Academic (GPT-5): GPT-5 proved to be much more measured, demonstrating better overall specificity (74%) and excelling at identifying subtle structural shifts like low-grade squamous intraepithelial lesions (LSIL) (75%) and glandular changes,. Yet, in its focus on the big picture, it completely missed obvious infectious organisms, scoring a dismal 20%,.• The Future of the Lab - Prompt Engineering & The Algorithmic Auditor: Why the next era of cytopathology requires rigorous AI fine-tuning on proprietary datasets and cytology-specific prompt optimization. We discuss a major paradigm shift where human pathologists may transition from actively hunting for disease to acting as "algorithmic auditors" whose primary job is to filter out the hyper-vigilant machine's noise,.Key Takeaway: Current multimodal LLMs are not yet reliable for independent Pap test interpretation due to critical blind spots and tendencies to overcall lesions,. However, their out-of-the-box performance establishes a staggering baseline. By understanding their unique mechanical flaws, pathologists can prepare to use these systems as highly effective co-pilots, seamlessly combining the algorithm's computational brute force with the indispensable filter of human medical reasoningSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: Artificial intelligence in oral oncology: Current advances and future potential in diagnosis, prognosis, and therapeutic decision-making. Annamalai A, Dhanes V, Jayalakshmi L, Shanmugam R, Ravi S. Cancer Treatment and Research Communications 47 (2026) 101193.Episode Summary: In this journal club deep dive, we explore how AI is fundamentally reshaping the clinical management of Oral Squamous Cell Carcinoma (OSCC). We examine a comprehensive March 2026 study that confronts a frustrating paradox: despite the oral cavity being visible to the naked eye, OSCC survival rates have stagnated due to late-stage diagnosis and complex tumor biology. This episode breaks down how algorithms are moving oncology from a reactive discipline to a highly predictive, personalized science.In This Episode, We Cover:• The OSCC Paradox: Why relying on traditional visual inspection and standard TNM staging ignores biological heterogeneity, and how AI steps in where the naked eye and basic anatomy fall short.• Pocket Pathologists: The revolutionary use of Convolutional Neural Networks (CNNs) in smartphone apps and portable devices, achieving up to 82% to 92% sensitivity for point-of-care screening in resource-constrained settings.• The Committee of Algorithms: How AI acts as a "multimodal synthesizer," fusing radiomics (tumor texture), histopathology (tumor-infiltrating lymphocytes), genomics, and Natural Language Processing (NLP) of unstructured clinical notes to predict individualized risk.• Real-Time Margin Guidance: How AI combined with fluorescent imaging provides surgical margin feedback to surgeons in the operating room in under five minutes with over 85% concordance with expert histopathologists.• Digital Twins: The sci-fi reality of running virtual clinical trials. We discuss how AI uses reinforcement learning to build simulated patient copies, allowing tumor boards to predict radiotherapy outcomes and drug toxicities before treating the physical person.• The Black Box, Bias, and the Fix: The major roadblocks preventing immediate clinical rollout. We discuss opaque decision-making and training data bias (which can drop accuracy by over 15% in underrepresented groups). We also explore the solutions: Explainable AI (Grad-CAM heat maps) to visualize decision logic, and Federated Learning (privacy-preserving decentralized training) to eliminate data sharing hurdles.Key Takeaway: The true value of AI in oral oncology isn't in replacing human clinicians, but in digesting massive multi-omics data that no single human could synthesize alone. By acting as a transparent, explainable support tool, AI is setting the stage for a future where tomorrow's healthcare professional might spend as much time treating a virtual patient as the physical one sitting in the chairSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: How artificial intelligence applied to digital pathology could guide treatment personalization in breast cancer. T. Ruelle, T. Grinda, L. Del Mastro, M. Lacroix-Triki, B. Pistilli & G. Gessain. ESMO Real World Data and Digital Oncology 2026.Episode Summary: In this journal club episode, we step into the reality of computational pathology and explore how artificial intelligence is fundamentally transforming breast cancer diagnostics. We examine a comprehensive review detailing how AI not only assists overburdened healthcare systems but also unlocks invisible genomic data straight from a standard $5 hematoxylin-eosin (H&E) glass slide. What happens when a machine can predict complex DNA mutations just by evaluating the structural architecture of cells?In This Episode, We Cover:• The Diagnostic Bottleneck: Understanding the critical worldwide shortage of pathologists colliding with a projected 3.2 million global breast cancer diagnoses by 2050, and why the system is under unprecedented strain.• The Biomarker Battle: Why the human visual cortex struggles to quantify faint immunohistochemistry stains, and how AI acts as a perfect "digital colorimeter". We discuss its near-perfect concordance in assessing crucial biomarkers like Ki-67, ER, PR, PD-L1, and the newly established HER2-low status.• Seeing the Invisible (Predictive AI): How deep learning transcends visual diagnostics to predict treatment outcomes, such as a patient's response to neoadjuvant chemotherapy. We also discuss AI's ability to infer Homologous Recombination Deficiency (HRD) and BRCA1/2 mutations by identifying macroscopic footprints like laminated fibrosis.• Decoding Genomic Assays: The potential to replace expensive, tissue-consuming genomic tests like Oncotype DX with AI models (such as Orpheus) that predict recurrence risk straight from digitized slides, achieving accuracy that rivals the tests themselves.• Roadblocks to Reality: The major clinical friction preventing global rollout. We discuss the steep infrastructure costs of whole-slide scanners, the danger of AI bias across diverse hospital datasets, and the ethical "black box" problem requiring the evolution of transparent, agent-based AI.Key Takeaway: Computational pathology is moving far beyond basic diagnostic assistance. By successfully reading the structural language of biology, AI proves it can extract costly, invisible molecular data from standard biopsies, fundamentally changing the economics and accessibility of global personalized healthcareSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailYou don't need a fancy scanner, a huge budget, or a computational background to get started in digital pathology. That's what I told the ACVP podcast — and I meant it. In this episode, I share my full digital pathology journey: from being completely intimidated by scanners during residency, to building a career that combines toxicologic pathology, image analysis, and remote work at a global CRO.If you're a resident, a trainee, or even a seasoned pathologist who hasn't fully stepped into the digital space yet — this one's for you.We talked about practical ways to get started, what foundation models actually mean for our daily work, how to build a team when implementing digital pathology at your institution, and why change management might be the most underestimated skill in this whole process.What we cover:[00:00] My background — from veterinary school in Poland to digital pathology[03:22] Why I chose industry over academia, and what that transition looked like[05:02] How a simple IHC side project became my entry point into digital pathology[07:11] How digital slides helped me pass my boards — and fall back in love with histopathology[10:24] My first job at a digital pathology image analysis company[12:00] What my current role at Charles River Laboratories looks like day-to-day[13:53] The best free resources for trainees to start exploring digital slides RIGHT NOW[15:26] Why pathologists need to understand image analysis principles — segmentation, classification, object detection[19:31] Foundation models, transformer architecture, and why annotation bottlenecks may soon be a thing of the past[24:13] Practical advice for institutions implementing digital pathology — equipment, teams, and managing resistance to change[27:30] How I unplug: trail running, weight training, and pathology-themed earringsResources & Links:Joint Pathology Center (JPC) digital slides: https://www.jpc.orgDavis Thompson Foundation — Noah Slidebox: https://www.davisthomasonfoundation.orgQuPath (free, open-source image analysis): https://qupath.github.ioDigital Pathology Place: https://www.digitalpathologyplace.comWatch the full conversation on YouTube: https://youtu.be/wTDdlxJzq-A?si=xkz5YNljrUX5SnhdSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailHow close is pathology AI to making decisions that matter in real workflows, real trials, and real patient care?In this episode of DigiPath Digest, I review five recent papers that approach that question from very different angles. We look at multimodal survival prediction in cervical cancer, pathology-driven response assessment in neoadjuvant immunotherapy for head and neck squamous cell carcinoma, AI-assisted Ki-67 scoring in pulmonary neuroendocrine neoplasms, automation and AI in hematologic diagnostics, and AI-based qFibrosis readouts from the Phase 3 MAESTRO-NASH trial.What I liked about this set of papers is that they do not all tell the same story. Some show clear progress. Some show where AI already works well as an adjunct. Others make it very clear that validation, governance, reproducibility, and workflow design still matter just as much as model performance.Key topics and timestamps00:00 Introduction, Easter edition, and community updates 00:51 USCAP recap, signed book giveaway, and free Digital Pathology 101 PDF 02:04 Partnerships, lab automation preview, and what's coming in this episode 03:25 Multimodal deep learning for cervical cancer survival prediction 13:00 Why pathology may be a better response endpoint than radiology in neoadjuvant HNSCC immunotherapy 23:09 Ki-67 scoring in pulmonary neuroendocrine neoplasms: pathologists vs two AI systems 33:46 AI, digital morphology, and automation in hematologic diagnostics 43:29 qFibrosis, digital biomarkers, and the MAESTRO-NASH Phase 3 trial 51:57 Closing thoughts, community updates, and Easter promotion Resources Deep Learning Can Predict the Overall Survival of Cervical Cancer Based on Histopathological Image, Gene Mutation and Clinical Information https://pubmed.ncbi.nlm.nih.gov/41902378/ Modern Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: From Residual Tumor Quantification to Spatial and AI-Based Biomarkers https://pubmed.ncbi.nlm.nih.gov/41899621/ Ki-67 Proliferation Index in Pulmonary Neuroendocrine Neoplasms: Interobserver Agreement Among Pathologists and Comparison of Two Artificial Intelligence-Based Image Analysis Systems https://pubmed.ncbi.nlm.nih.gov/41898274/ Molecular Pathology, Artificial Intelligence, and New Technologies in Hematologic Diagnostics: Translational Opportunities and Practical Considerations https://pubmed.ncbi.nlm.nih.gov/41897649/ Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial https://pubmed.ncbi.nlm.nih.gov/41895606/Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: High-Sensitivity Pan-Cancer AI Assessment of Lymph Node Metastasis via Uncertainty Quantification. Wang X, Chen Y, Liu X, et al. npj Digit. Med. (2026).Episode Summary: In this episode, we explore a groundbreaking 2026 study that tackles the "black box" problem of medical AI. We dive into UPATHLN, a pan-cancer AI platform for detecting lymph node metastases that doesn't just try to be right—it explicitly knows when it might be wrong. By using an innovative "uncertainty" fail-safe, this system achieved an unprecedented 100% sensitivity while drastically cutting down pathologist workload.In This Episode, We Cover:• The Needle in the Haystack Problem: Why finding cancer in lymph nodes is crucial for patient survival and therapeutic decision-making, and why the sheer volume of rising cancer cases is overwhelming human pathologists.• The Danger of "Overconfident Errors": How standard deep learning models stumble on rare, "long-tail" tumor variants. Standard AI is prone to making incorrect predictions with high certainty on data it hasn't seen before, leading to dangerous missed diagnoses.• Meet UPATHLN - The Unified AI: Moving away from fragmented, organ-specific AI to a single, foundation-model-powered platform trained and validated on a massive dataset of 26,229 lymph nodes across 14 distinct primary organs.• The "Fail-Safe" Mechanism (Uncertainty Estimation): How the researchers built a decoupled module that acts as a clinical safety net. Instead of forcing a guess, the AI flags "High Uncertainty" (HU) regions—like atypical cells or distracting elements like anthracotic pigment—and routes them directly for mandatory human review.• The Results - 100% Rescue Rate: In independent testing, relying on the AI's diagnostic probability alone would have missed 60 metastases. However, the uncertainty module successfully intercepted all 60 of these initially missed cases, achieving a 100% conditional sensitivity, even on 7 rare cancer types the AI had never seen before during training.• The Future of the Lab: How UPATHLN safely eliminated 73.2% of negative lymph nodes from manual review. By liberating pathologists from routine triage, the system frees up time for advanced, multi-dimensional precision oncology that goes beyond simple staging.Key Takeaway: The key to safe clinical AI isn't just raw accuracy—it's failure awareness. By teaching AI to explicitly model its own uncertainty, the system intercepted all missed diagnoses, handled rare biological variants safely, and established a trustworthy, workload-efficient partnership between human experts and artificial intelligenceSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Reliable classification of polyps based on artificial intelligence: a development and validation study. Julbø FMI, Henriksen AL, et al. eClinicalMedicine 2026;93: 103826.Episode Summary:In this journal club deep dive, we explore a groundbreaking 2026 study that tackles the massive bottleneck in gastrointestinal pathology caused by successful colorectal screening programs. We examine POLARIS, an AI triage system designed to safely clear over 50% of a pathologist's routine workload. But what happens when the algorithm fiercely disagrees with the human diagnosis? In a blinded showdown, the AI proves it's not just an efficiency tool—it might just be the ultimate safety net for catching high-risk cancer cells that human eyes overlook.In This Episode, We Cover:• The Pathology Bottleneck: Why the success of colorectal screening programs is drowning labs in biopsy slides, and how the subjective, visual nature of diagnosing polyps leads to dangerous inter-observer variability.• The 5:2 Triage Strategy: How POLARIS categorizes gigapixel slide images into five biological classes (0 to 4) and translates them into two highly actionable buckets: "Review" (the complex and malignant) and "No Review Required" (normal tissue and routine tubular adenomas with low-grade dysplasia).• Beating the "Clever Hans" Effect: How researchers prevented the AI from "cheating" by recognizing the digital fingerprints of different scanner brands, like Aperio vs. NanoZoomer. By using an image registration tool called elastix to perfectly align slides scanned on both machines, they heavily penalized the algorithm mathematically for relying on color profiles, forcing it to focus purely on biological morphology.• The Showdown - Humans vs. AI: A blinded consensus review was conducted on 40 highly contentious cases where the AI aggressively disagreed with the original patient medical record. Three independent expert pathologists were brought in to break the tie without knowing the AI's or the original doctor's diagnosis.• The Shocking Results: The expert panel sided with the AI over the original human diagnosis in a staggering 92.5% of the disputed cases, proving the established clinical "ground truth" isn't infallible.• The RGBA Heat Map: How POLARIS functions as an active assistant, leaving normal tissue transparent (scaling the alpha channel to zero) while highlighting severe cellular atypia in glowing red, acting as a hyper-accurate topographical map for pathologists.Key Takeaway:AI in digital pathology isn't about autonomously replacing human experts; it's a hyper-sensitive navigational aid. By safely managing the flood of routine low-grade cases and accurately highlighting hidden high-risk dysplasias that exhausted human eyes miss, POLARIS corrects human errors and elevates the baseline standard of diagnostic care across the entire pipeline.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: A Deep Learning Framework for Automated Triage of Breast Cancer Biopsies in Malaysia: A Simulation Study to Reduce Resource Consumption and Diagnostic Turnaround Time. Yudi Kurniawan Budi Susilo, Dewi Yuliana, Shamima Abdul Rahman, Siew Lian Leong. Clinical Breast Cancer 2026.Episode Summary: In this deep dive, we explore a revolutionary approach to a massive real-world healthcare bottleneck: agonizingly long diagnostic wait times in resource-constrained public hospitals. We unpack a 2026 study that bypasses strict patient privacy red tape by using AI trained entirely on synthetic, computer-generated breast tissue images. More importantly, the researchers built a "digital twin" of a Malaysian hospital to prove how an AI triage system could reorganize the diagnostic queue, catching aggressive cancers much faster while effectively conjuring new specialists out of thin air through massive time savings.In This Episode, We Cover:• The "FIFO" Bottleneck: Why the traditional First-In, First-Out workflow traps critical malignant biopsies behind a mountain of benign cases (which make up 70-80% of biopsies), acting like a trauma surgeon forced to treat paper cuts before looking at a major emergency.• Solving the Data Paradox with GANs: How the team used Generative Adversarial Networks (StyleGAN2-ADA) to forge 10,000 synthetic whole slide images, achieving such high statistical realism (FID < 25) that human pathologists were fooled and gave a >90% plausibility rating.• The AI Triage Engine: A look into the Convolutional Neural Network built on a pre-trained ResNet50 architecture. We discuss how it uses an attention-based Multiple Instance Learning (MIL) mechanism to break down billions of pixels into digestible patches, achieving a staggering 96.5% sensitivity—acting as a hyper-vigilant gatekeeper to ensure no cancers are missed.• Sim City for Pathology: How the researchers avoided testing on a live clinic and instead ran a Discrete-Event Simulation mimicking a chaotic public hospital for 250 days, factoring in chaotic arrival times and human reading delays.• The Shocking Results: The pure AI triage system plummeted turnaround time for suspicious cases by 38.3% (dropping from 7.24 days to 4.47 days), vastly outperforming hybrid or rule-based systems.• The Ripple Effect (Green Labs & Burnout): The system slashed pathologist workloads by 22.5% (saving 422 specialist hours annually) and reduced chemical reagent consumption by 15.2% by batch-processing the benign queue with standard chemicals.• The Reality Check: The critical limitations of synthetic data when faced with the messy realities of a physical hospital, including varying digital scanner color calibrations, IT infrastructure crashes, and local histological edge cases.Key Takeaway: AI in medicine isn't just about making the diagnosis—it's about fixing the workflow. By combining hyper-realistic synthetic data generation with discrete-event simulation, researchers proved that simply allowing an algorithm to sort a hospital's backlog can cut agonizing wait times for cancer patients by 38.3% and significantly relieve overburdened medical staff. The digital twin of the hospital is already here, and it might just hold the cure for systemic healthcare gridlockSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Ki-67 Proliferation Index in Pulmonary Neuroendocrine Neoplasms: Interobserver Agreement Among Pathologists and Comparison of Two Artificial Intelligence-Based Image Analysis Systems. Teoman G, Turkmen Usta Z, Sagnak Yilmaz Z, Ersoz S. MDPI 2026.Episode Summary:In this journal club deep dive, we step into the lab to examine a direct comparison between expert human pathologists and artificial intelligence. We explore a 2026 study that evaluates how two different AI image analysis systems score the critical Ki-67 biomarker in Pulmonary Neuroendocrine Neoplasms (PNENs) alongside four experienced human experts. Unlike stories where AI and humans clash, this study explores a different exciting reality: Can AI perfectly match the human gold standard to automate and standardize a highly tedious, labor-intensive medical process?In This Episode, We Cover:• The Diagnostic Challenge of Lung NENs: Understanding Pulmonary Neuroendocrine Neoplasms, a biologically diverse group of lung tumors ranging from slow-growing typical carcinoids to highly aggressive large cell neuroendocrine carcinomas. We discuss why precise classification is critical for predicting patient outcomes and guiding treatment.• The Spotlight Biomarker (The Speedometer): ◦ Ki-67: The definitive marker of active cellular proliferation, essentially acting as the tumor's "speedometer". While not formally incorporated into the WHO grading criteria for lung NENs, it is a vital clinical tool used to distinguish low-grade from high-grade tumors and identify biologically aggressive lesions.• The Showdown - Humans vs. AI: Four experienced pathologists go head-to-head with two digital heavyweights—the Roche uPath Ki-67 and the Virasoft Virasight Ki-67 algorithms. They analyzed 63 cases across different tumor subtypes, meticulously evaluating approximately 2,000 cells per predefined tumor hotspot.• Round 1 - Impressive Human Concordance: The human experts achieved near-perfect interobserver agreement (an Intraclass Correlation Coefficient of 0.998) when utilizing pre-selected hotspot regions, proving that standardized manual counting by experts is highly reliable.• Round 2 - AI Meets the Gold Standard: Both AI systems demonstrated massive, statistically significant correlations with the human experts' assessments. The AI reliably stratified the lung tumors into low, intermediate, and high-risk clinical categories without systematic bias, proving the algorithms can match human accuracy.• The Future of the Lab: Why AI shouldn't replace pathologists, but rather serve as a reproducible, objective assistant in the pathology lab. We discuss how automated AI analysis can reduce observer fatigue, enable rapid assessment of large tumor areas, and standardize testing across institutions, despite current roadblocks like algorithm complexity and a lack of wide accessibility.Key Takeaway:Artificial intelligence doesn't have to disagree with humans to prove its profound clinical worth. By successfully matching the excellent accuracy of top pathologists, these AI systems proved they can reliably handle the exhausting, subjective task of tumor cell counting. This paves the way for faster, highly standardized tumor evaluation, which could ultimately lead to more consistent and reliable prognostic diagnoses for lung cancer patientsSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailDeep Learning Can Predict the Overall Survival of Cervical Cancer Based on Histopathological Image, Gene Mutation and Clinical Information. Shen J, Miao Z, Wang L, et al. IET Systems Biology 2026.Episode Summary: In this deep dive, we explore a groundbreaking 2026 study that uses multimodal deep learning to act as a "master diagnostician" for cervical cancer. We examine what happens when an AI is fed a combination of standard clinical data, cutting-edge genetic sequencing, and century-old H&E tissue slides. The results force us to rethink how cancer operates: what happens when the genetic "blueprint" of a tumor lies to us, and the real biological truth is hiding in the seemingly chaotic pink and purple pixels of the connective tissue?In This Episode, We Cover:The Murky Diagnostics of Oncology: Understanding why predicting an individual patient's overall survival (OS) in cervical cancer is profoundly difficult. Getting this prediction wrong means risking either lethal undertreatment (distant metastasis) or subjecting stable patients to devastating overtreatment toxicities.The Three Modalities (The Suspect, The DNA, and The Security Footage):Clinical Data: The "suspect's description," utilizing standard patient metrics like age and tumor stage.Molecular Data: The genetic "blueprint" and somatic gene mutations. The AI isolated major red flags like RGR, DBN1, and CALCR mutations, which drive metastasis and signal poor prognosis.Histopathological Images (H&E): The "security footage" showing the physical tissue battlefield via whole slide images.The Model Showdown: Researchers trained a deep learning model (ResNet18) and fused these modalities using Multimodal Compact Bilinear (MCB) fusion. The AI was tasked with classifying patients into short-term (under 3 years) or long-term (over 3 years) survival, and it was rigorously validated on a completely independent dataset (PUMCH) to ensure generalizability.Round 1 - The Genetic Curveball: Despite being the cell's source code, genetic mutation data was the absolute worst predictor of survival, achieving an AUC of just 0.559. Adding it to the AI actually caused the "curse of dimensionality," making the model worse by overwhelming it with mathematical noise.Round 2 - The AI's "Aha!" Moment: The tissue phenotype dictates what actually happens. Fusing simple clinical data (age) with H&E images achieved a highly accurate 0.783 AUC. Even more shockingly, for aggressive short-term survival cases, the AI didn't focus heavily on the tumor itself. It looked at the stroma (connective tissue), deducing on its own that the host's inflammatory battleground dictates the lethality of the disease.The Future of the Lab: How automated quality control (HistoQC) and mathematical techniques (Macenko color normalization) strip away lab technician error and chemical dye variations. We also look ahead to how hyperspectral imaging might soon reveal the foundational chemical signatures of living cells.Key Takeaway: Throwing more data at an algorithm isn't always better. By successfully extracting profound biological truths from routine, inexpensive H&E slides, the AI proved that we don't necessarily need $1,000 genomic sequencing panels to accurately predict prognosis. The physical manifestation of the tumor microenvironment tells us exactly who is winning the battle, paving the way for accessible precision medicineSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Modern Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: From Residual Tumor Quantification to Spatial and AI-Based Biomarkers. Annabella Di Mauro, Rossella De Cecio, Saverio Simonelli, et al. Cancers (MDPI) 2026.Episode Summary: In this journal club deep dive, we explore a paradigm-shifting 2026 paper that fundamentally fractures our reliance on traditional radiology in head and neck cancer. We uncover a shocking clinical disconnect where seemingly devastating CT scans mask miraculous microscopic victories. When neoadjuvant immunotherapy unleashes the immune system, why does the tumor often look like it's growing on imaging? And how is pathology stepping out of the shadows to become the ultimate arbiter of biological truth, dictating precise surgical and medical oncology decisions?In This Episode, We Cover:The Trojan Horse of Imaging (Pseudoprogression): Why traditional CT scans are failing us in the immunotherapy era. Immunotherapy causes an influx of T-cells and inflammation that physically expands the tissue, tricking radiologists into diagnosing progressive disease when the cancer is actually being systematically dismantled from the inside out.The New Gold Standard - RVT: Why measuring the "shadow" of the tumor is obsolete. We discuss why pathologists are pivoting away from size and instead strictly quantifying Residual Viable Tumor (RVT) to determine the exact percentage of living, metabolically active carcinoma cells left behind.The "Starry Sky" Phenomenon: Tumors don't shrink like an ice cube melting from the outside in. We discuss how immune cells tunnel into the tumor, shattering it into a discontinuous "starry sky" pattern—scattered, radiologically occult microscopic islands of surviving cancer hidden across a vast sea of therapy-altered stroma.Compartmental Dissociation (The Nodal Force Field): A terrifying clinical reality where a patient can achieve a 100% complete pathological response at the primary mucosal site, but simultaneously harbor highly viable, proliferating cancer in their cervical lymph nodes. We explore how tumors hijack M2 macrophages to build a localized, cytokine-driven "force field" that neutralizes systemic T-cells the second they enter the node.The Future - High-Definition Spatial Biology: How AI-assisted digital pathology and spatial transcriptomics act as the "GPS tracking" or "sports analytics" of the tumor microenvironment. By mapping the exact coordinates of immune and cancer cells, tumor boards can confidently de-escalate toxic post-operative treatments for clear patients, or accurately target specific immunosuppressive resistance niches.Key Takeaway: Traditional imaging measures the volume of the battlefield, not the volume of the remaining enemy. By redefining therapeutic response through the microscopic lens of Residual Viable Tumor and AI-driven spatial biology, pathologists are no longer just staging dead tissue. They are now the central navigators of precision oncology, guiding the real-time escalation and de-escalation of patient care based on the true biological reality of the tumorSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: Molecular Pathology, Artificial Intelligence, and New Technologies in Hematologic Diagnostics: Translational Opportunities and Practical Considerations. Alnoor F, Mukherjee S, Menon MP, Ng D, Li P, Ohgami RS. Diagnostics 2026.Episode Summary: In this deep dive, we explore how hematology labs are tackling a massive rise in diagnostic complexity combined with persistent staffing shortages. The solution isn't just working harder—it's an entirely new workflow powered by robotics and AI. We unpack a comprehensive 2026 review that looks at the cutting-edge transformation of hematopathology, moving from manual microscopes to collaborative robots (cobots), digital morphology, and AI-driven genomic analysis. Can machines handle the grueling pre-analytical work and help experts diagnose leukemia faster and more accurately?In This Episode, We Cover:• The Modern Lab Crisis: How the latest WHO and International Consensus Classification (ICC) frameworks demand high-volume, multi-modal genomic and morphologic data, stretching human pathologists to their limits.• Enter the "Cobots": Collaborative robots are taking over the repetitive benchwork. We discuss systems like the UR5 cobots in Denmark that sort 3,000 blood tubes a day, and the Pramana Spectral HT robotic-arm scanners that digitize over 1,000 slides daily, freeing up human staff for higher-level tasks.• The Digital Eye (Morphology & AI): How platforms like CellaVision and Scopio turn glass slides into AI-analyzed data. ◦ Peripheral Blood: AI pre-classifies cells with 85-98% concordance to manual microscopy, prioritizing blasts and abnormal cells for expert review to improve efficiency. ◦ Bone Marrow: Deep learning isn't just counting cells; it's accurately quantifying reticulin fibrosis and identifying leukemia subtypes with human-level performance.• Flow Cytometry Gets an Upgrade: High-dimensional flow cytometry data meets deep learning. AI models are now achieving expert-level performance in classifying mature B-cell neoplasms and accurately distinguishing acute leukemias from non-leukemic samples.• The Molecular Frontier: AI is making sense of complex genomic datasets. We discuss breakthroughs like the MARLIN neural network, which achieves rapid epigenomic classification of acute leukemia in under two hours, and how AI assists in tracking measurable residual disease (MRD) longitudinally.• The Economics of Automation: Digital pathology is a smart financial investment. We review projections showing potential savings of $18 million over five years for integrated health systems, driven by improved efficiency, higher throughput, and fewer diagnostic errors.Key Takeaway: The integration of artificial intelligence and robotics is not meant to replace hematopathologists; rather, these technologies serve as essential scaling tools designed to absorb grueling physical labor and routine analytical tasks. By building a workflow where machines handle the sorting, scanning, and initial pattern recognition, experts can focus their time on final diagnostic synthesis—ultimately delivering faster, more precise patient careSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial. Schattenberg JM, Bedossa P, Guy CD, et al. Journal of Hepatology 2026; https://doi.org/10.1016/j.jhep.2026.03.021.Episode Summary: In this deep dive, we explore how artificial intelligence is revolutionizing the way we measure liver disease recovery. We examine a groundbreaking 2026 Phase III clinical trial (MAESTRO-NASH) that compared traditional human pathologist staging against an AI-driven digital pathology tool called qFibrosis. The study forces us to reconsider our clinical gold standards by asking: what if AI can detect subtle biological healing that the experienced human eye completely misses?In This Episode, We Cover:• The Silent Epidemic: Understanding Metabolic dysfunction-associated steatohepatitis (MASH), a progressive, active form of fatty liver disease linked to cardiovascular risk and cirrhosis. We discuss why precisely tracking the reversal of liver fibrosis is crucial for patient outcomes.• The "Ordinal" Problem: Why the current "gold standard"—human pathologists assigning a simple ordinal score (like Stage F1, F2, or F3)—is subjective and fails to capture the dynamic, nuanced reality of fibrosis progression and regression.• The AI Microscope (SHG & qFibrosis): ◦ SHG (Second Harmonic Generation): An imaging technique that takes advantage of the physical properties of collagen to map out the three-dimensional architecture of the liver. ◦ qFibrosis: An AI-driven analysis tool that evaluates up to 184 distinct features of liver collagen (like string length, width, and intersections) across different regions of the liver lobule, providing a continuous, hyper-detailed assessment rather than a basic category.• The Showdown - Humans vs. AI: Using data from 966 patients in the MAESTRO-NASH trial, we compare how human pathologists and the AI evaluated liver biopsies at baseline and week 52 to test the efficacy of the drug resmetirom.• The AI's "Aha!" Moment (Seeing the Invisible): The most shocking finding of the study occurred in the "non-responder" group. Even when human consensus reads declared certain patients had no histological improvement, the AI detected significant, continuous reductions in liver fibrosis (qFC scores). The digital pathology tool was able to pick up on subthreshold, early matrix remodeling that was entirely invisible to standard manual scoring.• Mapping the Liver's Healing: The AI proved its biological accuracy by successfully linking its spatial data to real-world clinical outcomes. The AI found that specific regional changes—particularly in the portal tract—strongly correlated with non-invasive liver stiffness tests like Magnetic Resonance Elastography (MRE).Key Takeaway: AI isn't here to replace human pathologists; it is a hyper-sensitive tool designed to uncover hidden data patterns. By detecting continuous, region-specific changes in liver collagen, AI digital pathology can identify early therapeutic responses to MASH treatments that traditional staging misses, fundamentally changing how we track disease reversal and personalize medicineSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: Digital Twins in Neuro-Oncology: A Systematic Review of Current Implementations, Technical Strategies, and Clinical Applications. Annie Singh, Fatima Ahmad Qureshy, Angelica Kurtz, Moinak Bhattacharya, Prateek Prasanna, and Gagandeep Singh. Radiology: Imaging Cancer 2026; 8(2).Episode Summary: In this journal club deep dive, we explore a groundbreaking 2026 systematic review of digital twins in neuro-oncology. We step past the buzzwords and examine how exact virtual copies of patient brains are being built to safely simulate dangerous radiation regimens and drug combinations for highly aggressive tumors. This forces us to ask an uncomfortable question: Are we just slapping the label "digital twin" on static algorithms, or are we actually building living, continuously updating virtual copies of patient tumors? Furthermore, what happens to clinical ethics when a perfect simulation predicts a patient's tumor will resist every standard line of therapy before they even try it?In This Episode, We Cover:• Defining the True Twin: We break down what separates a standard, static computational model from a true digital twin. A real digital twin requires closed-loop optimization with continuous, real-time feedback from a patient's actual biological response—a critical feature shockingly missing in 13 out of the 21 reviewed models.• The Dominance of Old-School Math: Why the most advanced simulations aren't relying solely on modern machine learning, but rather mechanistic models built on reaction-diffusion differential equations. We explain how these models calculate variables like tumor cell density, proliferation rate, and tissue carrying capacity to simulate literal physical pressure in the brain. Transparency and trust trump "black box" AI when neuro-oncologists are making life-altering surgical decisions.• The AI Visual Forecaster: How cutting-edge AI diffusion models, like BrainMRDiff and ImmunoDiff, serve as hybrid partners to these math equations. These tools take complex biological calculations and generate high-fidelity, anatomically consistent visual MRIs to accurately forecast how a tumor will morph post-treatment.• Grading Their Own Homework: A look at the PROBAST risk of bias assessment, which revealed that while outcome accuracy seems high, many models suffer from overfitting, data leakage, and a massive lack of external validation.• The Big Bottlenecks - Broken Pipes and Locked Safes: We discuss the roadblocks keeping this out of the bedside. Specifically, the glaring lack of open-source code (only 6 of 21 studies shared theirs) makes standardization impossible. We also examine the engineering nightmare of multimodal data fusion—combining asynchronous streams of MRIs, genomics, and tissue pathology into a real-time model.Key Takeaway: While digital twins represent a monumental leap toward true precision medicine, the field is currently bottlenecked by proprietary secrecy and broken data infrastructure. Until the scientific community embraces open-source code sharing and hospital systems solve the complex engineering challenge of real-time multimodal data integration, these revolutionary tools will remain isolated research projects rather than the living clinical tools they are meant to beSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailWhy do digital pathology projects get harder once the real workflow starts?In this USCAP 2026 conversation, I talk with Robert Moody from Hamamatsu and Jake Eden from Agilent about what the conference theme, MAKING CONNECTIONS, looks like in actual digital pathology implementation. This was not just a conversation about products. It was a conversation about workflow. We talked about why consistent staining matters before scanning, why strong partnerships need a shared vision, and why labs increasingly want a simpler point of contact as they move into digital pathology.  One point I really liked is that the value of a partnership is no longer just in combining components. It is in reducing complexity for the lab. Robert and Jake explain how vendors increasingly act as guides during digital transformation, helping customers navigate technical decisions, implementation steps, and the many stakeholders involved beyond pathology itself. That includes IT, information security, legal, finance, and lab operations. Another key theme is that no two deployments look the same. Some labs are centralized. Some are hub-and-spoke. Some outsource parts of the workflow. That is why future-proofing came up so strongly in this episode. Jake talks about keeping options open with open, agnostic workflows, and Robert makes the practical point that the most expensive thing you can do is the same implementation twice. Key highlights[00:22] Why this episode moves from high-level partnerships to what they look like in the lab [02:33] Why staining consistency matters for successful digital workflows [03:14] Shared vision, relationships, and why partnerships start with people [05:29] The idea of a single point of contact to reduce complexity for labs [08:32] Why vendors have become digital pathology guides [10:03] Why every deployment is unique [14:22] Future-proofing and choosing open, agnostic workflows [15:46] Why doing the same implementation twice is the expensive mistake to avoid Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan Mail Why does digital pathology adoption move faster in some places than others? In this USCAP 2026 conversation, I sat down with Robert Moody and Fumiya Fuji from Hamamatsu to talk about what the conference theme, MAKING CONNECTIONS, really looks like in practice. This was not just a scanner conversation. It was a workflow conversation. We talked about why digital pathology has shifted from a scanner-first mindset to a solution-first one, and why that matters for labs trying to build workflows that actually work. Robert explained why partnerships now need to happen earlier, with software, hardware, and execution teams involved from the start. Fumiya added a global perspective, comparing adoption drivers across the US, Japan, Europe, and Canada, and explaining why local support systems, ROI, geography, and government backing can all change the pace of adoption.  One point I especially liked was this: digital pathology is not one product. It is an ecosystem. And if one component fails, the whole workflow can break down. That is why connected thinking matters so much right now. This episode is really about how companies, labs, and partners are learning to work more like a team.  Key highlights [00:00] Why MAKING CONNECTIONS fits digital pathology so well [01:37] Why partnerships matter beyond the scanner [04:29] The shift from scanner-first to solution-first[04:58] How adoption differs across the US, Japan, Europe, and Canada [09:01] Why global collaboration inside Hamamatsu matters [10:50] How partnerships move from paper to real-world execution [12:55] Why does the USCAP show floor show a more connected industry [14:37] Why the next phase of digital pathology depends on interoperability and connected workflows Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailWhat makes digital pathology feel so hard to enter, even for smart people already working around it?In this special USCAP conversation, Stephanie Fullerton from Hamamatsu turns the tables and interviews me about Digital Pathology 101 — the book I wrote for people who are starting or continuing their digital pathology journey.We talk about why the book is not meant to be an exhaustive manual, but a practical framework. A way to help people see the full picture, ask better questions, and understand how the pieces of digital pathology fit together. One of the biggest themes in this conversation is that digital pathology is a team effort. It is not just pathology. It involves scanners, software, image analysis, engineers, vendors, and people who often do not speak the same professional language. That matters because sometimes getting the right answer starts with asking the right question.  We also talk about the challenge of translating expert knowledge into beginner-friendly language, why vendors often become guides as labs go through digital transformation, and why I think a shared vocabulary can make implementations smoother and more collaborative. Toward the end, we shift into the fun side of USCAP: signed book giveaways, stickers, pins, and ways to make connections at the conference.  Topics discussed[00:03] Why Stephanie interviewed me this time, and the idea behind Digital Pathology 101[01:07] What the book is actually for: a framework, not a one-size-fits-all manual [04:07] The hardest part of writing for beginners without talking down to them [06:26] Why digital pathology implementation feels like a mountain, and how to lower the barrier [08:15] Why a shared vocabulary matters in digital pathology teams [09:44] Translating between pathologists, engineers, vendors, and marketing [11:26] Why vendors and partners often become guides during digital transformation [12:33] Who the book is for, including students and early-career professionals [13:33] Book signing, giveaways, and where to find me at USCAP [19:05] Stickers, pins, and why small things can help start real conversations at conferences  Resources mentionedDigital Pathology 101Hamamatsu Booth 312 at #USCAP2026 in San Antonio, Texas  My histology and microscopy videos on YouTube Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:A comprehensive European Colorectal Cancer Cohort dataset. Holub P, Törnwall O, Garcia Alvarez E, et al. Sci Data (2026). https://doi.org/10.1038/s41597-026-06822-2.Episode Summary: In this journal club edition of the Digital Pathology Podcast, we explore a monumental effort to clear up the diagnostic "muddy waters" of Colorectal Cancer (CRC). We examine a groundbreaking 2026 paper detailing a massive European dataset of 10,780 CRC patients that provides an unprecedented "playground" for artificial intelligence. This episode asks how we can accurately predict cancer recurrence years down the line, and explores whether a 70-terabyte multimodal dataset might help algorithms uncover hidden biomarkers that could make traditional tumor staging completely obsolete.In This Episode, We Cover:• The "Gray Area" of Oncology: Understanding Stage II Colorectal Cancer, where primary tumors are removed but clear lymph nodes leave oncologists gambling on whether highly toxic chemotherapy is necessary to prevent microscopic recurrence.• A Continental AI Playground: A look at the sheer scale of the BBMRI-ERIC consortium's dataset: 10,780 patients from 26 biobanks across 12 countries, purposefully prioritized to include at least five years of clinical follow-up data.• The Three-Dimensional Disease Map: How the dataset links standard clinical records (the "street addresses") with Whole Genome Sequencing blueprints and 26 terabytes of gigapixel Whole Slide Images (the "satellite view") to give machine learning models a complete biological picture.• The Messy Reality of Raw Hospital Data: Why structural translation to OMOP and openEHR isn't enough. We highlight the terrifying logical errors caught by the consortium's automated plausibility scripts—from negative treatment durations to patients receiving chemotherapy after being marked as deceased.• Hacking GDPR for Rapid Research: How the project uses envelope encryption (Crypt4GH) and a 14-day "time-limited veto" system to securely grant researchers global, free access, proving that patient privacy and rapid scientific speed can seamlessly coexist.Key Takeaway: If deep learning algorithms trained on thousands of pristine digital slides and genomic blueprints can identify new morphological biomarkers and predict cancer recurrence with pixel-level accuracy, we may be looking at the beginning of the end for the century-old TNM staging system. This democratized dataset finally provides the massive statistical power needed to fundamentally redefine patient stratificationSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:The Performance of Artificial Intelligence in Classifying Molecular Markers in Adult-Type Gliomas Using Histopathological Images: Systematic Review. Almaabreh O, Al-Dafi R, Tabassum A, Othman A, Abd-alrazaq A. J Med Internet Res 2026; 28: e78377.Episode Summary: In this deep dive of the Digital Pathology Podcast, we explore the intersection of human limitations and computational power. Following the 2021 World Health Organization mandate requiring molecular data to diagnose adult-type gliomas, pathology has faced a massive bottleneck. Can artificial intelligence look at a standard pink-and-purple tissue slide and accurately predict hidden genetic mutations to serve as a diagnostic shortcut? We unpack a massive 2026 systematic review that evaluates the architectures, the "data diets," and the structural hurdles of using AI to "see the invisible".In This Episode, We Cover:• The 2021 WHO Diagnostic Shakeup: How the World Health Organization shifted glioma diagnosis from pure visual morphology (judging a book by its cover) to requiring precise genetic spelling (finding a typo on page 42), making the diagnostic process incredibly slow and expensive.• The Targets - IDH vs. 1p/19q: Why AI models are highly proficient at spotting the metaphorical "canyon" carved by early metabolic IDH mutations, but struggle to find the subtle visual clues of 1p/19q chromosomal codeletions.• The AI Toolkit - CNNs, MIL, and Transformers: ◦ CNNs (like DenseNet121): The heavy lifters of medical imaging, analyzing local cell structures and edges by constantly reusing foundational visual features. ◦ Multiple Instance Learning (MIL): The brilliant algorithmic solution to the excruciating human labor of pixel-by-pixel tumor annotation, allowing the AI to mathematically figure out what cancer looks like using only slide-level labels. ◦ Hybrid Models: By combining the microscopic focus of CNNs with the zoomed-out, global contextual awareness of Transformers, these models achieved the highest average accuracy at 92.80%.• The "Data Diet" and Domain Shift: The critical danger of training AI exclusively on single, homogeneous databases like the TCGA. We discuss why an algorithm that performs perfectly in a pristine "test kitchen" completely panics and drops in performance when faced with the varied stains, slice thicknesses, and scans of real-world community hospitals.• Multimodal Medicine: The revelation that AI models perform vastly better when fed diverse data streams, such as combining slide images with MRI scans and clinical notes. Implementing this necessitates a monumental structural integration between historically siloed hospital departments like radiology and pathology.Key Takeaway: AI is not replacing pathologists tomorrow; it is stepping into the co-pilot seat. While hybrid models show immense promise, their true standalone clinical adoption depends on breaking free from narrow training data, overcoming domain shift, and fundamentally restructuring our hospitals to feed these algorithms the multimodal context they need to thriveSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Artificial Intelligence and Its Applications in Oral and Maxillofacial Pathology. Veremis B. Dent Clin North Am. 2026 Apr;70(2):403-416.Episode Summary: In this Journal Club edition of the Digital Pathology Podcast, we explore a wild paradox at the bleeding edge of diagnostic medicine. We examine a 2026 paper on artificial intelligence in oral and maxillofacial pathology that reveals a fascinating reality: while highly advanced AI models can match human experts in detecting diseases, their clinical rollout is completely blocked by a surprisingly analog problem. We unpack why a 15-second difference in a laboratory dye bath might thwart billion-dollar neural networks and what this means for the future of the pathology lab.In This Episode, We Cover:• The Baseline - Matching Human Experts: How AI currently performs at human-expert levels for straightforward diagnostic tasks, such as detecting squamous cell carcinoma.• The Predictive Frontier (Prognostication): How AI goes beyond binary diagnosis to evaluate complex spatial relationships—like calculating the precise micrometer distance between every single tumor-infiltrating lymphocyte and the invading edge of a carcinoma. We discuss the holy grail of predicting malignant transformation in oral premalignant disorders.• The Analog Roadblock - Pre-analytical Variance: Why the physical, multi-step process of turning a tissue biopsy into a glass slide using H&E (hematoxylin and eosin) staining introduces massive data variability that severely confuses AI models.• The "Mojave Desert" AI Trap: How human brains abstractly interpret a dark pink cell, while an AI algorithm sees a fundamentally different mathematical environment of numerical RGB pixel values. We discuss why an algorithm trained perfectly on one lab's specific slides will completely fail when fed slides from a different lab with slight chemical variations, much like a self-driving car trained in the desert crashing in a blizzard.• The Data Drought: Why we desperately need millions of whole slide images from thousands of different laboratories to train robust, open-source AI models, and why these multi-institutional, standardized public datasets simply don't exist yet.• The Ultimate Dilemma for Local Labs: Will the inevitable adoption of AI diagnostic tools force independent pathology labs to abandon their unique, decades-old tissue preparation methods in favor of a single, universally mandated global standard for tissue fixation and staining?.Key Takeaway: The true bottleneck for AI in oral pathology isn't a lack of computational horsepower; it is analog inconsistency. Until the pathology field can standardize pre-analytical tissue preparation and build massive, publicly available datasets, highly sophisticated AI algorithms will remain isolated in the research lab instead of fulfilling their massive potential in everyday clinical diagnosticsSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailWhat happens when AI looks strong in a paper, but the workflow still isn't ready?In DigiPath Digest #40, I reviewed five recent papers across kidney pathology, oral and maxillofacial pathology, glioma biomarker prediction, digital twins in neuro-oncology, and a major European colorectal cancer cohort. A common theme kept coming back: good performance is not the same thing as real-world readiness.We started with kidney biopsies and the challenge of assessing interstitial fibrosis and tubular atrophy, where AI shows promise but still does not fully agree with humans. That led into a bigger point I keep seeing in digital pathology: our “ground truth” is often based on human interpretation, and human interpretation has variability too.From there, I looked at AI in oral and maxillofacial pathology, where the field is still early and one major bottleneck is the lack of strong public datasets. Then I discussed a systematic review on adult-type gliomas showing that multimodal models performed better than unimodal ones, which makes sense when you think about how pathologists actually work: we do not diagnose from one input alone.I also covered a systematic review on digital twins in neuro-oncology. The idea is exciting, but the paper makes it clear that reproducibility, public code, multimodal integration, and external validation are still limiting factors.And finally, I talked about a paper I really liked: a large European colorectal cancer cohort built across 26 biobanks in 12 countries. That kind of harmonized, quality-checked dataset matters. A lot. Because better AI starts with better data.In this episode, I discuss: Why AI vs human comparisons are harder than they first look  the “gold standard paradox” in pathology  Why multimodal AI keeps outperforming unimodal models  What is holding digital twins back from broader use  Why curated multicenter datasets are so important for digital pathology research Resources mentioned: Digital Pathology 101 pdf copy Pathology AI Makeover Course  DigiPath Digest AI-powered paper summaries Papers discussed:   https://pubmed.ncbi.nlm.nih.gov/41830415/https://pubmed.ncbi.nlm.nih.gov/41826004/https://pubmed.ncbi.nlm.nih.gov/41824546/https://pubmed.ncbi.nlm.nih.gov/41823607/https://pubmed.ncbi.nlm.nih.gov/41820399/Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Assessing interstitial fibrosis and tubular atrophy in kidney biopsies artificial intelligence versus humans. Farris AB, Zukić D, Solez K. Current Opinion in Nephrology and Hypertension. March 16, 2026.Episode Summary: In this journal club deep dive on the Digital Pathology Podcast, we explore the intense debate over quantifying chronic kidney disease progression. We unpack a fresh 2026 study comparing artificial intelligence to human pathologists in assessing interstitial fibrosis and tubular atrophy. If top experts can't agree on a diagnosis due to human subjectivity, can an AI trained on their imperfect data provide a better standard? We explore what happens when pixel-perfect machines clash with nuanced human medical judgment.In This Episode, We Cover:• The Clinical Stakes of Kidney Scarring: Why interstitial fibrosis (the scarring of tissue spaces between filtering units) and tubular atrophy (shrinking and collapsing functional tubes) are the primary surrogate measures for tracking chronic kidney disease. We discuss how a mere 10% diagnostic variance can drastically alter a patient's medication regimen, dialysis prep, or transplant eligibility.• The Flaw in the "Gold Standard": We break down the "interobserver variability" problem—why two highly trained, board-certified pathologists can look at the exact same biopsy slide and give two completely different mathematical assessments of the damage.• How the AI Actually Works (Mapping the Neighborhood): A look at "indirect assessment through kidney compartment segmentation," where the AI acts as a digital surveyor. It identifies cellular fences like glomeruli and tubules, establishing microscopic "zoning laws" before it begins counting the damaged tissue.• The Proofreader vs. The Literary Critic: Why studies show a persistent "lack of complete concordance" between human and machine. We discuss how AI hyper-focuses on mathematical pixel intensity and mistakes physical slide artifacts (like a folded piece of tissue) for severe disease. Meanwhile, human pathologists act as "literary critics," easily filtering out the visual noise using clinical context.• The Humans + AI Synergy: The ultimate endgame isn't replacing pathologists, but combining the tireless mathematical consistency of AI with the complex contextual reasoning of humans to create a highly advanced co-pilot system.Key Takeaway: The lack of perfect agreement between AI and human pathologists isn't a failure, but rather evidence that they perform fundamentally different types of analysis. AI excels at tedious, reproducible quantification that eliminates human visual fatigue, but it lacks contextual judgment. By adopting a "humans + AI" workflow, the medical field can stabilize crucial kidney measurements and elevate the pathologist to a true diagnostic synthesizer, ultimately leading to more effective patient careSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Clarifying validation terminologies in healthcare. Amanda Dy, Sandra M. Buetow, Andrew J. Bredemeyer, et al. npj Digit. Med. (2026). https://doi.org/10.1038/s41746-026-02471-2.Episode Summary:In this deep dive, we unpack the silent chaos surrounding a single, universally used word in healthcare innovation: "validation". Exploring a 2026 paper by the Pathology Innovation Collaborative Community (PIcc), we uncover how differing definitions of this word across AI developers, hospital directors, regulators, and venture capitalists can lead to massive miscommunications, millions of wasted dollars, and compromised patient safety. We ask the critical question: when a developer says an AI tool is "validated," what are they actually selling you?In This Episode, We Cover:• The "Chameleon Word" of Healthcare: Tracing the evolution of "validation" from its Latin roots, to its 1940s use in physical measurement accuracy, and its 1962 shift into hold-out testing. Today, the word functions simultaneously as an evidence claim, a lifecycle activity, and a quality label, creating a fractured meaning across disciplines.• The AI/ML Trap (Three Shades of Validation): Why an AI developer claiming a model is "validated" might just mean they checked the raw data for corrupt files (dataset validation) or tuned the model's math in the lab (validation data). Calling a model "validated" after internal cross-validation severely misrepresents its readiness for actual clinical deployment.• The Clinical Lab Reality Check (Analytical vs. Clinical): The crucial difference between analytical validation (proving a tool is technically perfect, like a thermometer) and clinical validation (proving the tool actually helps diagnose patients correctly). We also explore why the gold-standard US lab framework, CLIA, completely abandons the word "validation" in favor of establishing "performance characteristics" that require rigorous, site-specific verification.• The Regulatory and Business Minefields: How geography alters the legal definition, with the FDA focusing on intended use while European frameworks (IVDR) encompass entire lifecycle risk management. Furthermore, we discuss why "business validation" (securing investor funding) does not equate to clinical safety or regulatory readiness.• The "Lightweight" Solution: The authors don't propose a massive new dictionary; instead, they advocate for simple, lightweight qualifiers. Teams must stop using "validation" as a binary yes/no label and instead explicitly define the context—stating exactly what phase, reference standard, and operational conditions were tested.Key Takeaway:The word "validation" has morphed into a pseudoscientific label of trust that can mask a product's true readiness. To prevent dangerous misalignments in medical innovation, interdisciplinary teams must demand explicit context: never just accept that a tool is "validated" without asking "validated for what exactly?"Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Deep learning-based histopathological classification and subclassification of benign and malignant salivary gland tumors. Weber A, Schuster D, Heyer J, Becker C, Burkhardt V, Werner M, Spörlein A, Bronsert P, Schulz T. European Archives of Oto-Rhino-Laryngology 2026.Episode Summary: In this journal club deep dive of the Digital Pathology Podcast, we explore a chaotic microscopic landscape to see if artificial intelligence can master one of the most high-pressure diagnostic environments in medicine. We examine a groundbreaking 2026 study on rare salivary gland tumors, exploring how state-of-the-art AI models performed when tasked with distinguishing benign lesions from complex malignancies. We uncover where the AI achieved absolute perfection, where it catastrophically failed, and why its "mistakes" might just be a window into hidden biological truths.In This Episode, We Cover:• The High-Stakes Minefield of Salivary Glands: Why diagnosing these tumors is a delicate and complex task. With 36 potential entities and a practically zero margin for error, misdiagnoses can lead to devastating revision surgeries and permanent facial nerve palsy for the patient.• Training the Machine: How researchers used 20 years of slide data and the "Reinhard color normalization method" to mathematically standardize color palettes. This prevented the AI from "cheating" by simply memorizing fading colors or specific lab stains.• The AI Arsenal - CNNs vs. Vision Transformers: A look at the diverse algorithms deployed in the study, ranging from convolutional neural networks (like Xception and ConvNeXt) that scan local pixels, to Vision Transformers that analyze global image context, processing massive slides tile by tile.• The Perfection of Binary Triage: The stunning success of the AI in the initial benign vs. malignant test. Models like Xception achieved a 100% Negative Predictive Value (NPV), meaning they never missed a single cancer, proving their potential as a flawless morning triage tool for pathology labs.• The Subclassification Wall: Why the AI bombed when trying to identify the specific type of malignant tumor (like squamous cell or acinic cell carcinoma). We explore the deep learning rules of data volume and tissue heterogeneity, and why rare, morphologically chaotic diseases effectively starve algorithms of the data they need.• Explainable AI & The "Clever Hans" Dilemma: By using Class Activation Maps (heat maps), researchers tracked the AI's "eyes". While it often smartly focused on proven biological markers like enlarged, hypochromatic nuclei for cancer, it sometimes made correct diagnoses by staring at random, non-traceable artifacts, raising severe trust issues for clinical deployment.Key Takeaway: Deep learning models are currently fantastic, ultra-reliable screening assistants for binary benign/malignant triage, but they aren't ready to replace human pathologists for complex subtyping without massive, multi-institutional datasets. However, the AI's occasional focus on obscure visual data forces us to ask: is the machine just learning random artifacts, or has it successfully discovered subtle microscopic biological truths that human experts haven't even learned to see yet?Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:A confidence-based, artificial intelligence pathology model for diagnosis of intrahepatic cholangiocarcinoma. Chang, Jay, Calderaro, et al. Annals of Oncology 2026. DOI: 10.1016/j.annonc.2026.02.018.Episode Summary: In this journal club deep dive, we tackle one of the most frustrating diagnostic puzzles in liver cancer: differentiating primary intrahepatic cholangiocarcinoma (ICCA) from metastatic liver cancers. We examine a groundbreaking 2026 study introducing AI2CCA, a deep-learning pathology model that evaluates routine digitized slides. The study forces us to ask a critical question: how can we safely deploy AI in the clinic? The answer lies in teaching the machine to measure its own uncertainty, drastically reducing the need for invasive, exclusionary tests and accelerating life-saving treatments.In This Episode, We Cover:• The Ultimate Clinical Bottleneck: Understanding the high-stakes diagnostic overlap between ICCA and metastatic adenocarcinomas. Because these tumors look functionally identical—sharing irregular glandular structures, mucin secretion, and fibrotic responses—patients often face weeks of invasive endoscopies and body scans to rule out an occult primary site before targeted treatment can begin.• The Foundation Model Bake-Off: Researchers pitted three advanced, self-supervised deep learning architectures against each other using retrospective data from 544 patients across five European centers: ◦ Ctranspath paired with HistoBistro. ◦ UNI paired with CLAM. ◦ CONCH paired with TITAN, which emerged as the winner by mapping gigapixels of tissue to pathology reports using multimodal visual-language training.• The Secret Sauce - Predictive Entropy: An initial AUROC of 0.840 is not safe enough for clinical deployment. We break down how the team used Generalized-ODIN (G-ODIN) to calculate "predictive entropy"—a mathematical measurement of the AI's internal confusion when tissue is highly ambiguous.• The Power of Saying "I Don't Know": By setting a strict confidence threshold and refusing to diagnose ambiguous slides, the AI2CCA model improved its AUROC to 0.958 and dropped its false positive rate to absolute zero. While it only retained 46% of cases for high-confidence predictions, it provides a safe "fast-track" that could essentially halve the clinical backlog for unnecessary gastrointestinal scopes.• The Global Stress Test: To prove the AI didn't just memorize European lab stains, the team prospectively tested 161 new patients across France, India, and South Korea. Despite navigating completely different disease backgrounds—such as heavy cirrhosis and endemic liver flukes—the model achieved near-perfect accuracy (AUROCs of 1.00 and 0.965) with only one single misclassification globally.Key Takeaway: True clinical AI doesn't need to replace the human diagnostic process; it just needs to know what it doesn't know. By perfectly triaging 46% of routine cases with zero false positives, AI2CCA transforms the human pathologist into the ultimate biological arbiter, freeing up their cognitive bandwidth for the most complex cases while allowing thousands of patients to skip unnecessary invasive testsSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailArtificial Intelligence in Healthcare: From Diagnosis to Rehabilitation. Witek K, Nowocien M, Gerlach J, et al. Cureus 2026 Jan 25;18(1):e102286.Episode Summary: In this journal club deep dive on the Digital Pathology Podcast, we completely bypass the venture capital hype and science fiction narratives to look strictly at the hard clinical evidence surrounding artificial intelligence in medicine. We examine a monumental 2026 narrative review synthesizing a full decade's worth of data across the entire healthcare continuum—from diagnosis to rehabilitation. We explore the proven clinical benefits, the structural limitations, and the highly unpredictable reality of integrating these advanced algorithms into live clinical workflows.In This Episode, We Cover:• The Diagnostic Powerhouse: Why AI truly shines in visually intensive specialties like radiology, ophthalmology, dermatology, and digital pathology. We also unpack the crucial bottleneck: why algorithms that achieve board-certified performance in "open book" retrospective lab settings often struggle when faced with the messy, artifact-heavy reality of a live clinic.• Laboratory Medicine & LIS Optimization: How AI is functioning as a massive force multiplier behind the scenes. We discuss AI-driven lab test checkers that run continuous delta checks, acting as an algorithmic safeguard against inevitable human cognitive traps like anchoring bias during high-stress, 12-hour shifts.• Physical Rehabilitation & Robotics: AI stepping out of the computer monitor and interacting directly with the physical world. We explore robotic hand exoskeletons that process real-time electromyiography data to adapt to stroke patients millisecond by millisecond, and the use of large language models (LLMs) to design personalized therapy programs. We also discuss why massive multi-center prospective validation is required before these become the standard of care.• Conversational Agents (Chatbots): The delicate deployment of chatbots to bridge gaps in patient education and hold the line with immediate interventions for vulnerable individuals stuck on mental health waitlists. We emphasize why these agents must remain strictly as clinical adjuncts and triage tools, not replacements for empathetic human caregivers.• The Four Pillars of Friction: The massive structural hurdles preventing immediate global deployment: generalizability and algorithmic bias, the "black box" of algorithmic transparency, infrastructure limitations, and the scramble by organizations like the FDA and EU to establish proper regulatory oversight.Key Takeaway: The ultimate takeaway from a decade of data is that AI is a supportive clinical decision support technology, emphatically not a replacement for human healthcare professionals. The future of healthcare is the convergence of human and artificial intelligence; by letting algorithms absorb the heavy lifting of routine data verification, we may finally create the necessary breathing room to make clinical medicine profoundly human againSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode:Reporting checklist for foundation and large language models in medical research (REFINE): an international consensus guideline. Mese I, Akinci D'Antonoli T, Bluethgen C, et al. Diagn Interv Radiol 2026.Episode Summary: In this special journal club edition of the digital pathology podcast, we tackle a massive structural problem in medical imaging and AI: the rapid adoption of foundation models and large language models (LLMs) that are completely outgrowing our traditional evaluation frameworks. We examine the groundbreaking 2026 REFINE consensus guideline that addresses the opaque and stochastic nature of generative AI, forcing researchers to fundamentally change how they report on these tools to move away from black-box unpredictability toward true reproducibility.In This Episode, We Cover:• The "Wooden Ruler" Problem: Traditional AI reporting tools, such as CLAIM and TRIPOD-AI, were built under the assumption that algorithms are deterministic, meaning they give the exact same output every time. Generative AI is inherently stochastic and sensitive to subtle variables, making old checklists function like rigid wooden rulers trying to measure a fluid target.• The REFINE Framework: Created via a rigorous Delphi consensus process by 57 contributors from 17 countries, this robust 44-item, 6-section checklist is a massive global effort. It features a deliberate "N/A" filtering mechanism to practically accommodate highly diverse text, imaging, and multimodal study designs.• Prompting is the New Coding: We explore why researchers must now treat prompt engineering with the exact same rigor as traditional source code. The guideline requires full transparency on prompting strategies, session memory policies, and precisely how patient clinical context (like BI-RADS or ICD codes) is integrated into the model.• Corralling the Chaos (Stochasticity & The Human Element): Controlling an LLM requires detailing generation parameters like "temperature," which dictates model creativity. Crucially, studies must also document the prompt operator's characteristics, as a senior attending radiologist will intuitively guide a model very differently than a first-year resident, drastically skewing the output.• The Contamination Crisis: We discuss the existential threat of dataset contamination, which occurs when an LLM has already memorized public test datasets (like MIMIC-CXR) during its pre-training phase. The guideline demands rigorous checks against the model's knowledge cut-off dates and full transparency regarding the use of synthetic data.• Clinical Reality Check: A model's performance in a vacuum is meaningless if it cannot seamlessly integrate into a hospital's clinical workflow, such as its PACS. We detail why researchers must now explicitly outline clinical non-use cases, map out data privacy safeguards, and conduct formal failure analyses to categorize errors like hallucinations.Key Takeaway: The REFINE guideline marks a critical maturation point for medical AI research. By rigorously addressing the unique chaotic elements of generative AI—such as prompt sensitivity, stochastic generation, and dataset contamination—this framework ensures that future medical AI studies provide a trustworthy, reproducible foundation of evidence that frontline clinicians can safely rely on for patient careSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this AI Journal Club: "Transforming Gastric Biopsy Diagnostics: Integrating Omics Technologies and Artificial Intelligence" by Nasar Alwahaibi, published in the journal Biomedicines.Episode Summary: In this episode, we explore how traditional gastric biopsies are getting a massive, sci-fi-level upgrade. For over a century, diagnostic practice has relied heavily on visual pattern recognition via histomorphology—essentially looking at stained tissue under a brightfield microscope. Today, we discuss the paradigm shift toward data-driven "precision gastroenterology," made possible by merging high-resolution multi-omics technologies with the computational power of artificial intelligence (AI).Key Topics Covered:The Limits of the Status Quo: Traditional microscopic evaluation is foundational but limited. It suffers from interobserver variability (human disagreement), sampling limitations, and an inability to fully capture a tumor's biological complexity or predict how a disease will progress and respond to treatment.The Multi-Omics Revolution: Moving beyond basic static genomics to include transcriptomics, epigenomics, proteomics, and metabolomics provides a comprehensive map of cellular activity—what we call the "active construction site". We highlight a pivotal study by Kamio et al., which demonstrated that knowing a patient's specific TP53 mutation profile (such as the R175H mutation) in early-onset gastric cancer can predict a significantly longer time-to-treatment failure (17.3 months vs. 7.0 months) using oxaliplatin chemotherapy.AI as the Medical Co-Pilot: Deep learning models and convolutional neural networks (CNNs) are transforming both endoscopy and histopathology. For example, an AI-assisted tandem study showed a reduction in gastric neoplasm miss rates from 27.3% to an incredible 6.1%. Furthermore, AI tools have demonstrated the ability to outperform human experts in objectively scoring gastritis severity. However, it is crucial to remember that AI is currently a decision-support tool that still requires human oversight, especially in complex clinical realities.The "Endo-Histo-Omics" Paradigm: We dive into the future of integrated diagnostics, such as the HTML (Highly Trustworthy Multi-omics Learning) framework. This self-adaptive model dynamically tailors its computational architecture to prioritize the most reliable data from a specific sample's unique multi-omics and visual profile.Real-World Roadblocks: Before this becomes the standard of care at your local clinic, the medical field must overcome four main pillars of limitations: AI hurdles (data annotation burdens, black-box models), omics constraints (high costs, tiny biopsy sizes), integration complexity (lack of standardized software frameworks), and ethical/regulatory challenges (data privacy, algorithmic bias, and accountability).Conclusion: The traditional intuition of the pathologist is evolving as we transition toward personalized, multi-omics management. Keep questioning the data, exploring the mechanics of the science, and we will see you on the next episode!Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this AI Journal Club:From Image-Guided Surgery to Computer-Assisted Real-Time Diagnosis with Hyperspectral and Multispectral Imaging: A Systematic Review in Gynecologic Oncology. Innocenzi C, Pavone M, Seeliger B, et al. Diagnostics 2026.Episode Summary:In this journal club deep dive, we explore a groundbreaking 2026 systematic review that challenges the traditional intraoperative frozen section. We examine how hyperspectral and multispectral imaging are fundamentally reshaping the operating room by giving surgeons real-time, molecular-level vision. What happens when we can see beyond the visible spectrum, and how do we navigate the philosophical boundary between human surgical intuition and artificial intelligence?In This Episode, We Cover:• The End of the "Frozen Section" Waiting Game: Why current intraoperative pathology wastes precious surgical time and how "optical biopsies" provide cellular-level insight without the need for tissue contact, contrast agents, or freezing.• The Science of the Spectral Fingerprint: Moving beyond standard RGB monitors that limit what surgeons can see. How malignant tissues interact with light—through refraction, scattering, absorption, and fluorescence—to create unique optical signatures that our naked eyes completely miss.• Entering the Hypercube: How the 3D data sets of spectral imaging are captured: ◦ Spatial & Spectral Scanning: High-resolution methods that unfortunately struggle with breathing patients, making them susceptible to motion artifacts. ◦ Snapshot Technology: The real-time, video-rate method that balances spatial and spectral resolution for live clinical use.• Clinical Showdowns - Cervical and Ovarian Cancer: ◦ Cervical Neoplasia: How multispectral imaging tracks the dynamic whitening of tissue following acetic acid application, plummeting false-diagnostic rates to an astonishing 1.7% compared to the 20-24% error rates of traditional methods. ◦ Ovarian Cancer: The massive hurdle of surgical blood acting as an "optical sink" that confuses sensors by causing spatial heterogeneity, and how mathematical normalization techniques correct these specific errors. ◦ The Falloposcope: A look at miniaturized technology safely navigating the fallopian tubes, combining optical coherence tomography (OCT) and multispectral imaging to detect early-stage cancers right where they originate.• The "Black Box" and Spurious Correlations: Why feeding complex hypercube data into AI models (like CNNs and Random Forests) can be dangerous if the data sets are unbalanced. If an algorithm learns to diagnose cancer based on a spurious correlation like the glare of an OR light rather than actual biomolecular tumor markers, it will fail in new environments. We discuss the absolute necessity of Explainable AI (XAI) so surgeons can trust the biological plausibility of the machine's decisions.Key Takeaway: The integration of hyperspectral and multispectral imaging serves as a real-time optical biopsy, offering incredible sensitivity for detecting malignancies. By pairing these tools with transparent, explainable AI, we are standing on the precipice of a new era that will drastically improve patient outcomes and force us to redefine the future of surgical intuitionSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send a textIf AI can detect patterns we cannot see, how do we know when its answers are clinically trustworthy?In this episode of DigiPath Digest #39, I explore a big-picture question in digital pathology and medical AI. Many models now match or even exceed human performance in specific diagnostic tasks. But most of that evidence comes from controlled or retrospective datasets. So what happens when we try to bring these tools into real clinical workflows?I review four recent papers that help frame this challenge and point toward the next steps for trustworthy AI in healthcare. You will hear about the role of prospective validation, real-world effectiveness, transparent reporting standards, and multimodal data integration as recurring themes across these studies.Key Highlights00:00 – Introduction What do we do when AI detects signals that humans cannot see? The core challenge is verifying those outputs before trusting them in clinical decision making. 03:32 – AI Across the Healthcare Continuum A narrative review shows AI achieving clinician-level performance in well-defined imaging tasks, including digital pathology. But most evidence comes from retrospective or controlled environments, and prospective validation remains limited. 08:34 – Multi-Omics and AI in Gastric Biopsy Diagnostics Morphology alone cannot fully capture molecular heterogeneity or predict disease progression. Integrating genomics, proteomics, metabolomics, and other omics with AI is shifting gastric pathology toward data-driven precision gastroenterology. 13:38 – Hyperspectral Imaging for Real-Time Surgical Guidance Spectral imaging can analyze tissue composition during surgery without staining, freezing, or contact with the tissue. Studies show promising sensitivity for detecting malignancy and supporting intraoperative decision making. 17:20 – REFINE Reporting Guideline for Foundation Models and LLMs An international consensus guideline introduces a 44-item reporting checklist to standardize how AI studies are described. The goal is transparent, reproducible, and comparable research in medical AI. 22:35 – Big Takeaway AI should be viewed as clinical decision support, not a replacement for clinicians. Real-world validation, ethical governance, and reproducible research standards will determine how these tools enter pathology workflows. References (Articles Discussed)Artificial Intelligence in Healthcare: From Diagnosis to Rehabilitation https://pubmed.ncbi.nlm.nih.gov/41755929/Transforming Gastric Biopsy Diagnostics: Integrating Omics Technologies and Artificial Intelligence https://pubmed.ncbi.nlm.nih.gov/41751306/From Image-Guided Surgery to Computer-Assisted Real-Time Diagnosis with Hyperspectral and Multispectral Imaging https://pubmed.ncbi.nlm.nih.gov/41750768/REFINE Reporting Guideline for Foundation and Large Language Models in Medical Research https://pubmed.ncbi.nlm.nih.gov/41762555/If you enjoy staying current with digital pathology and AI research, this episode will help you connect the dots between promising algorithms and practical clinical adoption.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this AI Journal Club:Masry ME, Gnyawali S, Jacobson M, Xue Y, Sen C, Wachs J, Gordillo G. AutoMated Burn Diagnostic System for Healthcare (AMBUSH). Plast Reconstr Surg Glob Open. 2023 Oct 18;11(10 Suppl):128-129. doi: 10.1097/01.GOX.0000992564.42240.e3. PMCID: PMC10566867.Episode Summary: In this journal club deep dive, we tackle a clinical problem that has frustrated surgeons for decades: accurately diagnosing burn depth. We examine a groundbreaking study introducing AMBUSH-AI, an artificial intelligence system that evaluates ultrasound imaging to outperform the diagnostic accuracy of human experts. When the stakes are a lifetime of severe scarring from under-treatment versus the painful trauma of an unnecessary skin graft, can a combination of standard ultrasound and AI completely eliminate the dangerous guesswork of human visual inspection?.In This Episode, We Cover:• The Diagnostic "Coin Toss": Why distinguishing between deep partial and full-thickness (third-degree) burns is the ultimate clinical challenge. We discuss the terrifying reality that experienced burn surgeons only achieve about 76% accuracy in visual assessments, while non-experts sit at 50%—literally a coin toss.• The Two-Part Tech Combo (Anatomy and Stiffness): ◦ B-Mode Ultrasound: The standard imaging modality that provides the anatomical landmarks, letting the machine know exactly where the epidermis, dermis, and hypodermis are located. ◦ Tissue Doppler Elastography Imaging (TDI): The secret sauce that measures tissue stiffness. When skin burns, structural proteins denature and tangle, making the tissue physically stiffer. TDI visualizes this stiffness with color overlays—red for healthy and supple, blue for stiff and burned.• Finding the Ground Truth: Why you can't calibrate a new, precise tool against a broken ruler. Instead of comparing the AI to flawed human visual estimates, the researchers validated the AI against actual tissue biopsies taken in the operating room, establishing an undeniable histological reality.• The Results - Outperforming the Experts: In the human clinical trial, AMBUSH-AI achieved a staggering 95% overall accuracy. Crucially, it had a 100% sensitivity rate for surgical cases, meaning it did not miss a single patient who definitively needed an operation to prevent severe morbidity.• The AI's "Glass Box" Design: Why surgeons will never trust a mysterious "black box" that just spits out a diagnosis. AMBUSH-AI is designed as an explainable model; it outputs plain text explaining its reasoning (e.g., "dominant, continuous blue pattern is present in the hypodermis"), acting as a transparent decision-support tool rather than a robot replacement.• The Future of Triage: How this technology could be paired with Point of Care Ultrasound (POCUS) on portable tablets in military combat zones and rural ERs, giving any medic or general doctor the diagnostic confidence of a 20-year burn specialist.Key Takeaway: The era of subjective, visual wound assessment is ending. By successfully translating the physical stiffness of a burn into objective, AI-interpreted data—a process called "computational palpation"—we can dramatically improve triage accuracy, save vital hospital resources, and spare patients from both dangerous under-treatment and unnecessary surgical trauma.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this AI Journal Club:Benchmarking large language model-based agent systems for clinical decision tasks. Liu, Y., Carrero, Z.I., Jiang, X. et al. npj Digit. Med. 2026.Episode Summary: In this episode, we dive into a comprehensive 2026 benchmarking study that tests whether the highly hyped "Agentic AI" systems are truly ready to revolutionize clinical decision-making. We pit baseline large language models (LLMs) against complex, multi-agent systems in a series of rigorous medical exams and simulated doctor-patient dialogues. The big question: Do the autonomous planning and tool-use capabilities of AI agents actually translate to better diagnostic outcomes, or do they just add unnecessary computational bloat to the clinical workflow?In This Episode, We Cover:The Contenders - Baseline LLMs vs. AI Agents: Understanding the difference between a standalone LLM (like GPT-4.1, Qwen-3, or Llama-4) and "Agentic AI" systems (like Manus and OpenManus). Unlike simple chatbots, these agent systems are designed to autonomously reason, plan, and invoke external tools like web browsers, code executors, and text editors to solve complex clinical problems.The Clinical Gauntlet: How researchers tested these models across three grueling healthcare benchmarks: AgentClinic (step-by-step simulated diagnostic dialogues), MedAgentsBench (a knowledge-intensive medical Q&A dataset), and Humanity's Last Exam (highly complex, multimodal medical questions designed to defeat AI shortcut cues).The Verdict - Modest Gains: The surprising reality that despite their advanced, multi-step toolsets, agent systems only yielded a modest accuracy boost over baseline LLMs. We discuss how customized agent models peaked at 60.3% accuracy on AgentClinic MedQA, 30.3% on MedAgentsBench, and struggled at a mere 8.6% on the text-only Humanity's Last Exam.The Computational Price Tag: Why deploying these agents in a real hospital setting might be completely impractical right now. We discuss the massive inefficiency of these systems, noting that agents like OpenManus consumed more than 10 times the tokens and required more than double the response time compared to a standard LLM.The Hallucination Problem: Exploring the persistent and dangerous issue of AI "making things up," such as inventing patient statements or assuming test results without asking the patient. We look at how researchers used targeted prompt engineering and an LLM-based output filter to successfully block 89.9% of these clinical hallucinations, though the core problem remains prevalent.Key Takeaway: While Agentic AI systems show promise by autonomously gathering data and using external tools, their modest accuracy improvements are currently overshadowed by massive computational demands, increased response times, and persistent hallucinations. They represent a step forward in clinical AI architecture, but they remain too inefficient and unrefined for the fast-paced, high-stakes reality of routine clinical deployment.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this AI Journal Club:Wienholt, P., Caselitz, S., Siepmann, R. et al. Hallucination filtering in radiology vision-language models using discrete semantic entropy. Eur Radiol (2026). https://doi.org/10.1007/s00330-026-12384-zEpisode Summary: In this deep dive, we strip away the marketing hype surrounding medical AI and confront the "black box" problem of Vision Language Models (VLMs) like GPT-4o. We examine a groundbreaking 2026 study published in European Radiology that tackles a terrifying clinical issue: these AI models are incredibly confident, articulate, and often completely wrong. We explore a clever new mathematical wrapper designed to catch the AI in a lie, forcing us to ask: how do we stop the AI from hallucinating with dangerous authority, and can we actually teach it to say "I don't know"?In This Episode, We Cover:• The Confident Liar Problem (The Baseline): Why generalist VLMs are fundamentally different from traditional, narrow medical AI. They are probabilistic engines designed to predict the next word, resulting in a dangerous baseline accuracy of just 51.7% on real-world clinical data—essentially a coin flip.• The Mathematical Lie Detector (Discrete Semantic Entropy): How turning up the AI's "temperature" to 1.0 and asking the exact same question 15 times forces the model to brainstorm, revealing its hidden uncertainties.• Semantic Clustering (Cutting through the Noise): If the AI says "pneumonia" and then "lung infection," human clinicians know it means the same thing. We discuss how the DSE algorithm groups these answers by their underlying clinical meaning to calculate whether the AI is confidently consistent (low entropy) or randomly guessing (high entropy).• The Coverage Cost vs. Accuracy Trade-Off: The dramatic results of applying a strict DSE filter. GPT-4o's accuracy jumped from roughly 51% to over 76%, but with a massive catch—it remained completely silent on over half the cases, answering only 47.3% of the clinical questions.• The Danger Zone (Where AI Fails): Breaking down the performance across modalities. While the AI shone at identifying organs and surprisingly excelled at angiography, it completely fell flat on abnormality detection. On complex 3D CT scans, the filter had to reject over 90% of the questions because the model was fundamentally confused.• The Trap of the "Confident Hallucination": Why DSE measures consistency, not truth. We explore the nightmare scenario where an AI stubbornly hallucinates the exact same lie 15 times in a row, slipping past the safety filter and creating a massive risk for "automation bias" among clinicians.• Clinical Feasibility: The surprising practicality of running 15 parallel queries in a real hospital workflow. Because they run simultaneously via an API, the safety check takes only 6 seconds and costs roughly $0.72 per question.Key Takeaway: Building safer AI might paradoxically risk creating riskier doctors. While Discrete Semantic Entropy successfully filters out the AI's digital noise and confusion—transforming a failing model into a somewhat reliable, albeit very quiet, assistant—it leaves us with a critical human factors challenge. If the system flawlessly cherry-picks the easy cases and stays silent on the hard ones, we must ensure our own diagnostic muscles don't atrophy from over-trusting the machine.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this Episode: A Deep Learning Framework for Automated Triage of Breast Cancer Biopsies in Malaysia: A Simulation Study to Reduce Resource Consumption and Diagnostic Turnaround Time. Susilo YKB, Yuliana D, Rahman SA, Leong SL. Clinical Breast Cancer 2026.Episode Summary: In this journal club deep dive on the Digital Pathology Podcast, we explore a 2026 study tackling severe diagnostic bottlenecks in breast cancer care. Facing a critical shortage of pathologists and agonizing patient wait times, researchers in Malaysia designed a deep learning triage system. But here is the major twist: they trained their highly accurate AI entirely on fake, synthetic tissue. We examine how this virtual simulation could revolutionize resource-constrained healthcare systems and ask a profound philosophical question: are the most powerful medical tools of tomorrow going to be built from the digital ghosts of patients who never even existed?In This Episode, We Cover:• The FIFO Problem: Why the standard "First-In, First-Out" (FIFO) laboratory queue is failing patients, burying urgent malignancies under routine benign cases (which make up 70-80% of biopsies), and causing excruciating turnaround times of over 14 days.• The AI Triage Solution: How researchers used a Convolutional Neural Network (based on ResNet50) combined with an attention-based Multiple Instance Learning (MIL) mechanism to analyze massive whole-slide images and automatically bump suspicious cases to the front of the line.• Training on "Digital Ghosts": The wild reality of Generative Adversarial Networks (GANs) like StyleGAN2-ADA. To bypass privacy laws and data scarcity, the AI was trained on 10,000 completely synthetic biopsy slides that were mathematically so realistic, expert human pathologists gave them a plausibility rating of over 90%.• The Virtual Hospital: How researchers built an in-silico Discrete-Event Simulation using a Python library called SimPy. By inputting real-world hospital parameters, they created a digital twin to safely stress-test their AI without risking real patient lives.• Transformative Results: The simulation projected a 38.3% reduction in wait times for critical cancer cases and a massive 22.5% drop in pathologist workload (saving over 422 hours annually). It also highlighted a 15.2% decrease in toxic reagent use, proving AI can support green laboratory sustainability initiatives.• The Reality Check: Why this incredible simulated blueprint still needs rigorous real-world clinical validation before it can overcome the physical, messy inconsistencies—like tissue folds, scanner downtime, and variable stains—of a live laboratory.Key Takeaway: Algorithmic queue management can fundamentally transform resource-constrained health systems. By proving that a highly accurate, cancer-detecting AI can be trained on purely synthetic data, this study offers a compelling blueprint to bypass privacy hurdles and data scarcity, drastically cutting diagnostic delays and saving vital specialist hoursSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send us Fan MailPaper Discussed in this AI Journal Club:Region-Based Segmentation of Lymph Node Metastases in Whole-Slide Images of Colorectal Cancer: A Pilot Clinical Study. Fayzullin A, Savelov N, Balkivskiy A, et al. Cancer Medicine 2026.Episode Summary: In this deep dive, we strip away the marketing gloss of AI as a mere time-saving tool and look at its true value in the lab: saving lives through relentless vigilance. We examine a 2026 study on colorectal cancer that deploys a two-stage AI pipeline to hunt down microscopic lymph node metastases. By highlighting "Specimen 8"—a speck of cancer hidden within a busy, benign background—we explore why the real return on investment for AI in digital pathology isn't about speeding up the human, but acting as an automated safety net that catches what the human eye naturally misses.In This Episode, We Cover:• The 12-Node Burden: The grueling clinical reality of staging colorectal cancer, where pathologists must manually scan at least 12 regional lymph nodes for microscopic tumor cells—a perfect storm for change blindness and visual fatigue.• The Mimics of Pathology: Why finding metastases isn't just looking for a "needle in a haystack," but fighting visual mimics like sinus histiocytosis that effortlessly camouflage tiny, poorly differentiated cancer cells.• The Two-Stage AI Pipeline ("The Scout" and "The Artist"): ◦ The Scout (GoogLeNet): A lightweight classification model that acts as a binary filter, achieving a staggering 100% recall by scanning image tiles and successfully filtering out confusing artifacts like tissue folds. ◦ The Artist (DeepLabV3+): A heavy-duty semantic segmentation model that draws precise boundaries around viable tumor cells while intelligently ignoring necrosis and lakes of mucin.• The Hardware Validation Test: How the researchers proved their AI's robustness by testing it across different hardware (Hamamatsu and Leica scanners) to avoid the "silent killer" of AI projects: domain shift from scanner variability.• The "Specimen 8" Revelation: A breakdown of the crucial moment the AI caught a 0.14 mm by 0.06 mm metastasis hiding in a benign pattern. The AI didn't save the pathologists time here—it actually slowed them down to verify—but it prevented a catastrophic misdiagnosis.• The Return on Investment (ROI) Myth: Why hospital administrators need to stop looking at AI strictly for turnaround time speed. The study proved overall time savings were essentially negligible (1-3 seconds per case), but the quality assurance and patient safety derived from catching missed cancers were priceless.Key Takeaway: The true value of AI in pathology isn't in racing the clock; it's in absolute vigilance. By successfully highlighting microscopic metastatic mimics that cause human false-negatives, AI proves its worth not as a turbo-button for the lab, but as a tireless quality assurance partner that ensures accurate cancer staging and optimal patient outcomes.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send a textClinical Artificial Intelligence in 2026. Accuracy, Education, and GuardrailsArtificial intelligence is evolving fast in medicine. But how accurate is it. And are we building it safely?In this episode of DigiPath Digest, I review five new studies shaping digital pathology, radiology, burn diagnostics, and agent-based large language model systems. We discuss accuracy gains, hallucination filtering, education challenges, and why safeguards are essential before clinical deployment.Clear. Practical. Evidence-based.⏱ Topics & Timestamps[00:02] Introduction Weekly journal club on digital pathology and artificial intelligence.[05:13] Hallucination Filtering in Radiology Using Discrete Semantic Entropy to detect hallucination-prone responses in Vision Language Models. Accuracy improved from 51.7 percent to 76.3 percent after filtering high-entropy answers.[15:04] Artificial Intelligence in Pathology Training Supervised use during residency. Balancing artificial intelligence adoption with preservation of morphological analysis and critical thinking.[20:12] Colorectal Cancer Lymph Node Detection Two-stage classification and segmentation model in Whole Slide Imaging. Recall 1.0. Specificity 0.935. Dice coefficient 0.818. Artificial intelligence as a second opinion.[25:04] Burn Depth Prediction with Artificial Intelligence Tissue Doppler Elastography and Harmonic B-mode ultrasound combined with artificial intelligence. 90 to 95 percent accuracy in human subjects.[31:20] Agent-Based Large Language Model Systems OpenManus and Manus evaluated in clinical simulations. Up to 60.3 percent accuracy. High computational cost. 89.9 percent of hallucinations filtered by safeguards.[40:08] Patient Access to Pathology Images Why viewing pathology slides can empower patients and improve communication.Resourceshttps://pubmed.ncbi.nlm.nih.gov/41720937/https://pubmed.ncbi.nlm.nih.gov/41720644/https://pubmed.ncbi.nlm.nih.gov/41716065/https://pubmed.ncbi.nlm.nih.gov/41709317/https://pubmed.ncbi.nlm.nih.gov/41708802/Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Send a textWhat if one of the biggest sources of diagnostic variability in prostate cancer isn't the pathologist—but the stain we've trusted for decades?In this episode, I speak with Professor Ingied Carlbom, founder of CADESS.AI, about a different way to approach prostate cancer grading—by rethinking staining, segmentation, and AI decision support from the ground up. We explore why 30–40% interobserver variability persists in Gleason grading and how optimized stains combined with explainable AI can significantly reduce that uncertainty.Ingred shares her journey from applied mathematics and computer science into pathology, the skepticism she faced in 2008, and why CADESS.AI chose not to “optimize H&E,” but instead developed a Picrosirius red + hematoxylin stain designed specifically for computational pathology. We discuss how grading at the gland and cellular level improves reproducibility, why explainability matters for trust, and what it really takes to build both stain and software as a single diagnostic workflow.This conversation challenges long-held assumptions—and asks whether improving data quality should come before building smarter algorithms.Highlights:[00:00–01:08] The problem: 30–40% disagreement in prostate cancer grading[01:08–03:03] Ingrid's path from applied math to digital pathology[03:03–04:58] Early skepticism toward AI in pathology and fear of replacement[04:58–08:56] Why H&E limits segmentation—and how a new stain changes that[10:55–15:09] Clinical testing: non-inferiority, AI assistance, and NCCN risk stratification[19:47–22:59] Explainable UI: color-coded glands and pathologist override[26:16–27:29] Why grading glands (not whole slides) reduces variability[38:09–41:47] Regulatory challenges of combined stain + AI devices[45:52–48:55] The future of optimized stains in routine pathologyResources from This EpisodeCADESS.AI – Prostate cancer decision support systemNCCN prostate cancer risk stratification guidelinesSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Send a textSometimes a paper comes out that's so practical and relevant to what we do in digital pathology that I know we have to talk about it.In this episode, I dive into “A Guide for the Deployment, Validation and Accreditation of Clinical Digital Pathology Tools” from Geneva University Hospital (HUG) — one of the most useful, real-world frameworks I've seen for bringing digital pathology tools safely into clinical practice.If you've ever built an AI model and wondered, “Now what?”, this episode is for you. Because building the model is often the easy part — deployment is where things get complex.This guide breaks the process into four practical phases every lab can follow:1️⃣ Pre-Development – Define your clinical need, project scope, and validation plan before writing a single line of code. 2️⃣ Development – Build and integrate the algorithm in a production-ready environment. 3️⃣ Validation & Hardening – Turn your research code into a reliable, secure, and compliant clinical tool. 4️⃣ Production & Monitoring – Keep the tool validated and performing consistently over time.We also discuss what makes qualification, validation, and accreditation different — and why that order really matters. You'll hear about the multidisciplinary team behind these deployments, especially the deployment engineer (DE) — the technical linchpin who turns AI research into clinical reality.I share the story of HUG's H. pylori detection tool, which cut diagnostic time by 26% while maintaining a 0% false negative rate. The team's secret? Careful planning, quality control, and continuous user feedback — not just great code.Other highlights include:Why integration often takes longer than building the AI model itselfHow to avoid invalidating your validation dataWhat continuous performance monitoring looks like in real labsAnd why every lab still needs to do local validation, even with proven toolsIf you're working on digital or computational pathology tools — or just want to understand how AI safely moves from research to routine diagnostics — this episode will give you a roadmap grounded in real experience.

Send a textIs AI in pathology actually improving diagnosis — or just adding complexity?In DigiPath Digest #37, we reviewed four recent publications covering AI-based biomarker quantification in glioblastoma, real-world digital workflow integration in prostate cancer, multimodal AI combining histopathology and genomics, and patient perspectives on AI in cancer diagnostics.This episode connects technical performance with something equally important: trust.Episode Highlights[00:02] Community & updates Digital Pathology 101 free PDF, upcoming patient-focused book, and global attendance.[04:07] AI-based image analysis in glioblastoma AI showed strong consistency with pathologists when quantifying Ki-67, P53, and PHH3. Significant biological correlations (Ki-67 ↔ PHH3, PHH3 ↔ P53) were detected by AI — not by manual assessment. Takeaway: computational quantification improves precision.[09:28] Real-world digital workflow + AI in prostate cancer (France) AI-pathologist concordance: • 93.2% (high probability cancer detection) • 99.0% (low probability slides) Gleason concordance: 76.6% 10% failure rate due to pre-analytical artifacts. Takeaway: infrastructure and sample quality still matter.[15:58] Multimodal AI (MARBIX framework) Combines whole slide images + immunogenomic data in a shared latent space using binary “monograms.” Performance in lung cancer: 85–89% vs 69–76% unimodal models. Takeaway: integrated data improves case retrieval and similarity reasoning.[22:13] AI-powered paper summary subscription introduced Structured summaries for busy professionals who want more than abstracts.[26:17] Patient roundtable on AI in pathology (Belgium) Patients expect: • Better accuracy • Faster turnaround • Stronger collaborationTrust is high when: • Algorithms use diverse datasets • Pathologists retain final responsibilityClinical validity mattered more than full algorithm transparency. Privacy concerns focused more on insurer misuse than cloud transfer.Key TakeawaysAI improves biomarker precision in glioblastoma.Digital pathology implementation works — but pre-analytics can limit AI performance.Multimodal AI represents the next meaningful step in precision diagnostics.Patients are not afraid of AI — they want validation, oversight, and governance.Human–AI collaboration remains central.If you're working in digital pathology, computational pathology, or precision oncology, this episode connects evidence, implementation, and patient perspective.Support the showGet the "Digital Pathology 101" FREE E-book and join us!